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ABSTRACT
Correlates of Human Papillomavirus (HPV) Vaccine Acceptance in Appalachian Tennessee
by
Oluwatosin Ariyo
Human papillomavirus (HPV) is the most prevalent sexually transmitted infection in the U.S.,
where one HPV-related cancer is diagnosed every 20 minutes. The most common HPV-related
cancer is cervical cancer, with an estimated incidence of 12,000 cases annually, a third of which
lead to death. Cervical cancer disparately affects women of ethnic minority groups and
geographically isolated regions, such as Appalachia. Tennessee ranks third highest in cervical
cancer incidence in the country. Many cases of cervical cancer could be prevented through
vaccination against HPV, however, vaccination rates for females in Tennessee are among the
lowest in the country. This mixed-methods study included an in-depth exploration of the factors
that influence HPV vaccine acceptance in Appalachian Tennessee.
Healthcare providers, mothers of adolescent girls, and college-aged women were recruited to
participate in the study. From October 2016 to January 2017, interviews were conducted with
healthcare providers (n=12), focus groups were conducted with mothers (n=13), and a survey
was administered to college women (n=479). Interview and focus group sessions were recorded,
transcribed and analyzed using a thematic framework. Survey responses were analyzed using
descriptive tests, comparison of means, and regression analyses.
The predominant barriers to vaccine acceptance identified in the study were: cost and novelty of
the vaccine, vaccine safety, lack of school-entry requirement, and the implication of vaccine
acceptance on adolescents’ sexual activity. Most negative perceptions towards the vaccine
2

appeared to be propagated by the sociocultural influence on sex and reproductive health
communication within the community. Perceived benefits for cancer prevention and receipt of
strong and personal provider recommendations facilitated vaccine acceptance. Additionally,
college students who reported vaccine acceptance reported discussing sexual health topics with
their mothers more often than those who had not been vaccinated.
The findings from this study provide foundational insights about the facilitators and barriers of
HPV vaccine acceptance in Appalachian Tennessee. Identifying and understanding these factors
is crucial to improving HPV vaccination rates and essential to maximizing the primary benefit of
the vaccine in addressing the existing cervical cancer disparity in the region.
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CHAPTER 1
INTRODUCTION
Background of the Study
Human Papillomavirus (HPV) is the most common sexually transmitted infection (STI)
in the U.S. (CDC-Centers For Disease Control and Prevention, 2014) About 25% of the current
U.S. population are currently infected with HPV, with an estimated 14 million new cases
occurring each year (CDC-Centers For Disease Control and Prevention, 2014). HPV is so
widespread that nine out of ten people will be infected in their lifetime (CDC-Centers For
Disease Control and Prevention, 2014; National Cancer Institute, 2016). Of the 200 types of
HPV, over 40 are sexually transmitted and can be categorized as either low or high risk (CDCCenters For Disease Control and Prevention, 2014; National Cancer Institute, 2016; Vamos,
McDermott, & Daley, 2008). The low-risk HPV types cause skin warts around the genitals,
mouth, throat, and anus, while the high-risk types can cause cancer and account for over half of
HPV infections (National Cancer Institute, 2016). Every 20 minutes, one HPV-related cancer is
diagnosed in the U.S., the most common of which is cervical cancer (CDC-Centers For Disease
Control and Prevention, 2014). Women between the ages of 20 and 24 years have the highest
prevalence (45%) with incidence increasing with age, particulalry between the ages of 14 to 24
years old (American Cancer Society, 2017; National Cancer Institute, 2016; Vanderpool, Casey,
& Crosby, 2011). Cervical cancer is the third most common gynecologic cancer and the second
leading cause of cancer mortality in young women between the ages of 20 and 39 years old
(CDC-Centers For Disease Control and Prevention, 2017).
With the development of the HPV vaccine, these viral infections can be prevented. The
effectiveness of the vaccine is optimized when received by adolescents before their first sexual
12

encounter (Brewer et al., 2013; CDC-Centers For Disease Control and Prevention, 2014;
National Cancer Institute, 2016; Smith et al., 2013). Although the vaccine has proven to be
almost 100% effective in preventing the development of cancerous cells in the cervix, low
vaccination rates among adolescent women in the U.S. are still a public health concern (Brewer
et al., 2013). These low vaccination rates are of particular concern among underserved
populations such as Appalachian women, who experience a disproportionate burden of HPVrelated cancers and high cervical cancer incidence and mortality (Blackley, Behringer, & Zheng,
2012; Brewer et al., 2013; Casey, Crosby, Vanderpool, Dignan, & Bates, 2013; Reiter, Fisher, et
al., 2013; Reiter, Katz, & Paskett, 2012).
Some of the barriers that impede vaccine acceptance among underserved populations
such as cost of the vaccine, lack of insurance, limited access to health services, and limited
knowledge about HPV and the vaccine are often associated with low socioeconomic status and
rurality (Holman et al., 2014). Individuals with low educational attainment often have low health
literacy levels and low income levels, which further encumber their capacity to afford health
services. In addition, residents of rural communities have limited access to health care facilities.
Previous studies have demonstrated that mothers play a significant role in maintaining
the health of their family (Krieger et al., 2013; Roberts, Gerrard, Reimer, & Gibbons, 2010). The
role of mothers is especially relevant in the uptake of vaccinations among adolescents, as
maternal influence and endorsement have been shown to be predictors of young women’s
decision to receive the HPV vaccine (Krieger, Kam, Katz, & Roberto, 2011; Roberts et al.,
2010). Among Appalachian women, this decision to receive the HPV vaccine is further
influenced by factors within their social, cultural and economic environments (Brewer et al.,
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2013; Casey et al., 2013; Head & Cohen, 2012; Hutson, Dorgan, Duvall, & Garrett, 2011b;
Mills, Head, & Vanderpool, 2013; Vanderpool et al., 2011).
Purpose of the Study
Low HPV vaccination rates among young women in the Central and South Central
Appalachian regions of the U.S., also referred to as rural Appalachia, place them at an increased
risk for HPV and cervical cancer. While affordability of the vaccine is often cited as a barrier for
low-income populations, such as those in rural Appalachia, studies have shown that even when
cost is controlled for, vaccine uptake is still low in these regions (Crosby, Casey, Vanderpool,
Collins, & Moore, 2011; Vanderpool et al., 2011). This phenomenon suggests the influence of
other factors within the socio-ecological system. Studies have been conducted in Appalachian
Ohio (North Central Appalachia) and Kentucky (Central Appalachia) in order to identify these
factors, but only a limited body of knowledge investigating similar factors exists in Tennessee
(Central and South Central Appalachia). Appalachian sub-regions are often categorized based on
cultural and socioeconomic differences (Reiter et al., 2012), therefore it is important to identify
and understand the specific barriers and predictors of HPV vaccine acceptance within each subregion.
This study is an in-depth exploration of the broader context within Appalachian
Tennessee, with the primary objective to gain an understanding of the underlying themes that
influence HPV vaccine acceptance. In addition to the low social and economic status (education,
income, availability of health services) often associated with geographically isolated areas,
health status and outcomes among women in rural Appalachian regions are also predicted by
cultural values. These values are often exhibited in interpersonal networks, with mothers as the
primary influencers within these networks (Hutson, Dorgan, Duvall, & Garrett, 2011a; Hutson,
14

Dorgan, Phillips, & Behringer, 2007a). Considering these regionally-specific factors and the role
of mothers in their daughters’ health, it is pertinent to assess the correlation of sociocultural
factors and mother-daughter communication with HPV vaccine acceptance in rural Appalachia.
Additionally, since mothers often depend on recommendations from healthcare providers, and
provider recommendation in Appalachia is lower than in non-Appalachian regions, it is
important to understand the factors that drive provider attitudes towards vaccine
recommendation.
While some studies have investigated HPV vaccination rates in Appalachia compared to
their non-Appalachian counterparts (Kahn et al., 2007; Krieger, Katz, Kam, & Roberto, 2012;
Roberto, Krieger, Katz, Goei, & Jain, 2011), fewer studies have explored the factors that
influence vaccine acceptance within a multi-sectoral context. Likewise, some studies have
investigated the role of mother-daughter communication in vaccine acceptance (Krieger et al.,
2011; Roberts et al., 2010), but none have examined this relationship among mothers and
daughters in rural Appalachia. Therefore, the purpose of this study is to utilize a conceptual
framework that accounts for the impact of factors across the healthcare system, interpersonal
networks, and sociocultural context on vaccine attitudes and behaviors in rural Appalachia.
Conceptual Frameworks Guiding the Study
A multi-sectoral systems model provides a conceptual framework to depict the systemic
interactions of various factors that influence HPV vaccine uptake within the healthcare system,
family context and community culture (Figure 1). Within the healthcare system, vaccine uptake
is influenced by a provider’s recommendation, which is largely influenced by the provider’s
attitudes and beliefs towards the vaccine (Gilkey & Mcree, 2016; Kahn et al., 2007; Krieger et
al., 2012; Roberto et al., 2011). A provider with ambivalent or negative attitudes towards the
15

HPV vaccine is less likely to recommend it to patients, or could directly discourage it. The
community culture in which a provider practices also has a major effect on their attitudes and
beliefs. Healthcare providers who practice in communities where the HPV vaccine is equated
with promiscuity are more likely to have negative attitudes towards the vaccine or anticipate
negative reactions from parents, and are thus less likely to recommend the vaccine (Krieger et
al., 2012). Low provider recommendation further perpetuates low levels of awareness and
negative attitudes about the vaccine within the community context, propagating the notion that, if
a health professional has concerns about the vaccine, these ‘expert-based concerns’ must be valid
and should be heeded.

Healthcare
system

Community
culture

Family
context

Figure 1: Model of Multi-Sectorial Systems Thinking

Within the family context, a parent’s or a young woman’s decision to receive the vaccine
is influenced by their socioeconomic status, attitudes and beliefs about HPV, the vaccine and
cervical cancer, and ultimately by interpersonal relationships (Hutson et al., 2011a; Mills et al.,
2013; Vanderpool, Dressler, Stradtman, & Crosby, 2015). Her literacy levels and ability to
access health information influence a mother’s knowledge about the vaccine. Her attitudes
towards the vaccine are, in turn, influenced by norms and cultural values, and her ability to
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receive the vaccine is influenced by her income and access to health services (Katz et al., n.d.;
Reiter, Katz, & Paskett, 2013).
Within each of these sectors, the individual-level factors that facilitate or inhibit HPV
vaccine acceptance can be further assessed using the Integrated Behavior Model (IBM). The
IBM provides a theoretical framework to describe individuals’ perceptions and attitudes that
predict their intentions to receive or recommend the HPV vaccine. This model is derived from
overlapping constructs contained in five prominent theories of health behavior (Theory of
Reasoned Action, Theory of Planned Behavior, Social Cognitive Theory, Theory of
Interpersonal behavior, and the Health Belief Model). The IBM offers relevant constructs which
are crucial precursors to preventive health behaviors like HPV vaccine uptake (Head & Cohen,
2012; Montaño & Kasprzyk, 2008). These constructs include: attitudes, beliefs, knowledge,
norms, personal agency, environmental constraints and intention (Figure 2). For instance,
knowledge, awareness and normative influences concerning HPV would shape a mother’s beliefs
about the vaccine and subsequently impact her intention to accept the vaccine for her daughter.
Similarly, these constructs would influence a young woman’s intention for receipt, and a
healthcare provider’s intention to recommend the vaccine (Head & Cohen, 2012). The IBM
model also provides a conceptual framework to depict how an individual’s attitudes and beliefs
about receiving/recommending the HPV vaccine are influenced by knowledge and awareness
about the virus and the vaccine, the effect of normative influences within their interpersonal
networks (defined as endorsement of the vaccine by significant figures in a woman’s life), and
environmental factors within the community context which further facilitate or impede vaccine
uptake. These constructs are depicted in figure 2 below, boxes in bold represent constructs that
will be assessed in the study aims.
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In accordance with the purpose of the study, the multi-sectoral and IBM models provide
the theoretical foundation to explore individual-level factors within the healthcare system, family
context and community culture, associated with HPV vaccine acceptance in rural Appalachia,
develop measures to test these factors, and identify overlapping factors across each sector.
Additionally, the models serve as a vehicle to identify leverage points for action and serve as a
framework to develop culturally-relevant, evidence-based programs to eliminate identified
barriers associated with the HPV vaccine.

Figure 2: Integrated Behavior Model Depicting Factors That Influence HPV Vaccine Acceptance

Research Aims
This study aims to add to the body of knowledge about factors associated with suboptimal HPV vaccination rates among rural Appalachian women. Considering the disparate
burden of cervical and other HPV-related cancers in most of rural Appalachia, and the existence
of a primary prevention tool in the HPV vaccine to address this health problem, it is of particular
concern that the vaccine is not readily accepted among this high-risk population. Therefore, this
study seeks to explore the underlying factors of low vaccine uptake among women in
Appalachian Tennessee.
18

Healthcare providers, mothers and young women are the primary actors in the
conversation around HPV vaccine acceptance and uptake. Parents, adolescents and providers are
influenced by their mutual interactions with each other; effective communication among this
triad has been shown to positively influence vaccine acceptability and increase uptake (Hughes,
Jones, Feemster, & Fiks, 2011). Adolescents are primarily dependent on their mother’s
endorsement and support of the vaccine, as well as their provider’s recommendation, to initiate
vaccine uptake. Mothers, in turn, are also influenced by clinician’s recommendation and social
norms within their interpersonal networks. Clinicians are influenced by normative influences
within their practice and their community context. Based on this evidence, it is important to elicit
a comprehensive understanding of factors that influence HPV vaccine acceptance among women
and providers in Appalachian Tennessee.
The knowledge gained from this study can be applied to increase vaccination rates and
would substantially aid in preventing cervical cancer among this population with a disparate
burden of cervical cancer (Reiter, Fisher, et al., 2013). To achieve this overarching goal, the
specific aims of this study are to:
Research Aim I
Explore HPV vaccine-related attitudes and perceptions among a sample of healthcare
providers within Appalachian Tennessee.
Research Aim II
Explore attitudes, perceptions, knowledge and awareness related to the HPV vaccine
among Appalachian mothers.
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Research Aim III
Measure vaccination rates and assess attitudes, perceptions, knowledge and awareness
related to the HPV vaccine among a sample of young women who fall within the recommended
age range (≤26 years) for vaccine dose completion.
Research Aim IV
Explore associations between mother-daughter sexual health communication and vaccine
acceptance in Appalachian Tennessee.
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CHAPTER 2
LITERATURE REVIEW
Human Papillomavirus
Etiology and transmission. Human papillomaviruses (HPVs) are a group of wide and
diverse viruses (Bzhalava, Guan, Franceschi, Dillner, & Clifford, 2013). Each virus in the group
is characterized by a number, which is called an HPV type. There are almost 200 identified HPV
types, with continuous discovery of new types (Bzhalava et al., 2013). These viruses adapt to the
tissues of their host and commandeer the human cellular mechanism for their viral replication
and maintenance (Muñoz, Castellsagué, de González, & Gissmann, 2006). An HPV infection
begins when the virus enters the basal layer of the epithelium through cuts or abrasions in the
skin, and then proliferates throughout the infected region, destroying healthy host cells in the
process (Muñoz et al., 2006). The virus is primarily transmitted through dermal contact and can
be contracted through vaginal, oral or anal sex. HPV can be transmitted from infected persons
who are symptomatic or asymptomatic (CDC-Centers For Disease Control and Prevention,
2014).
Epidemiology. HPV is a very common infection and is the most prevalent STI in the U.S.
with about 25% of the U.S population currently infected and an estimated 5% new cases
diagnosed every year (CDC-Centers For Disease Control and Prevention, 2014). All sexually
active males and females can get HPV, and most will be infected at some point in their lives
(CDC-Centers For Disease Control and Prevention, 2014). The prevalence of HPV in the U.S. is
highest among young women, with increasing prevalence between the ages of 14 to 24 years,
peak prevalence below 25 years, decreasing prevalence between ages 35 to 54 years, and a
second peak after 55 years (Baseman & Koutsky, 2005; Roberts et al., 2010; Vanderpool et al.,
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2011). HPV prevalence in women over the age of 30 is mostly due to persistent infections
(Baseman & Koutsky, 2005). The incidence of HPV is highest among sexually active young
adults with increasing incidence soon after sexual debut.
Number of sexual partners is the primary risk factor for HPV infection (American Cancer
Society, 2016; Baseman & Koutsky, 2005; CDC-Centers For Disease Control and Prevention,
2014). Studies have shown a strong positive association between lifetime number of sexual
partners and HPV infection in both males and females. Studies have also shown that HPV
infection in a woman is positively associated with the number of her male partner’s lifetime
sexual encounters, with increased incidence among women whose partners have multiple
partners. Uncircumcised males have a higher risk for HPV infection, as do their female partners.
Other factors that may be associated with increased risk of HPV infection are suppressed
immunity (either due to disease or drugs that weaken the immune system) and smoking
(Baseman & Koutsky, 2005).
HPV-Related Diseases. HPVs are responsible for a number of diseases ranging from
benign lesions to malignant tumors. Each HPV type is further classified into groups depending
on which membrane of the skin it often infects and the type of disease associated with the
subsequent infection. Those that infect the moist surface layers that line organs and cavities in
the human body are called mucosal HPV types, and those that infect the skin are called
cutaneous HPV types (American Cancer Society, 2016; Bzhalava et al., 2013). Approximately
75% of identified HPV types are cutaneous, and about 25% are mucosal. These groups are
further subdivided into oncogenic low-risk and oncogenic high-risk (American Cancer Society,
2016). The cutaneous types are often oncogenic low-risk and usually cause skin warts around the
hands and feet (American Cancer Society, 2016). Some high-risk cutaneous types have also been
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found in non-melanoma skin cancers (NMSCs) such as basal and squamous cell carcinoma
(Bzhalava et al., 2013). The mucosal types, also known as (ano)genital types because they are
often found in the anal or genital regions, can either be high-risk or low-risk (American Cancer
Society, 2016). The low-risk types (HPV 6 & 11) often lead to genital warts, while the high-risk
types (e.g. HPV 16 & 18) can lead to cancers of the cervix, vulva, anus, vagina, penis, throat,
tongue and tonsils (American Cancer Society, 2016; Bzhalava et al., 2013). Cervical cancer is
the most common HPV-related cancer (CDC-Centers For Disease Control and Prevention,
2014). The International Agency for Research on Cancer (IARC) recently classified 12 mucosal
types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59) as ‘high-risk’ due to their
association with cervical cancer (Bzhalava et al., 2013; International Agency for Research on
Cancer, 2012).
Cervical Cancer
Etiology. Strong epidemiological evidence has established the role of HPV in cervical
cancer incidence; HPV is a primary and necessary cause of cervical cancer (Crosbie, Einstein,
Franceschi, & Kitchener, 2013; Muñoz et al., 2006). A woman must be infected with HPV to
develop cervical cancer. While this infection could be from any of the high-risk types, about
75% of cervical cancer cases are caused by HPV16 or 18. HPV infections can be asymptomatic
and may clear without treatment. However, sometimes the infection persists and leads to the
formation of pre-cancerous cells (American Cancer Society, 2014). Not all pre-cancerous cells
become invasive cancers, but progression is unpredictable and could develop in a space of a few
months or years (American Cancer Society, 2014). There are four major steps in the
development of cervical cancer: HPV infection of the epithelial layer, viral persistence,
progression of persistent infections to pre-cancerous cells, and invasion of the epithelial
23

membranes (Schiffman, Castle, Jeronimo, Rodriguez, & Wacholder, 2007). Once HPV begins
proliferation in the epithelial layers, it causes the production of two proteins (E6 and E7) which
inactivate tumor suppressor genes (American Cancer Society, 2014; Muñoz et al., 2006). This
process promotes accelerated growth of epithelial cells lining the cervix thus causing precancerous cell transformation (Muñoz et al., 2006).
Epidemiology. Cervical cancer is the third most commonly diagnosed gynecologic cancer
in the U.S. and the second leading cause of cancer mortality in women between the ages of 20 to
39 years old (Rauh-Hain et al., 2013) The current incidence rate of cervical cancer in the U.S. is
7.7/100,000 women, which translated to an estimated 12,990 new cases and 4,120 deaths in 2016
(American Cancer Society, 2017). The estimated mortality from cervical cancer (31.7%) in the
U.S is almost double that of breast cancer (16.3%). Cervical cancer is more prevalent among
women in their middle ages, and rarer in women older than 50 years, although more than 15% of
cervical cancer cases occur in women over 65 years who have not being regularly screened
(American Cancer Society, 2014).
Established risk factors that are associated with cervical cancer incidence are: smoking,
long term use of oral contraceptives, high number of full-term pregnancies, poverty and
immunosuppression (American Cancer Society, 2014; Muñoz et al., 2006). Women who smoke
are almost twice as likely to develop cervical cancer compared to non-smokers. Tobacco
molecules have been found in the cervical mucus of smokers (American Cancer Society, 2014).
Based on this evidence, researchers suggest that tobacco damages the DNA of cervical cells thus
contributing to the development of cancer (American Cancer Society, 2014). Additionally,
smoking compromises the immunity of smokers making their immune systems less effective in
clearing HPV infections (American Cancer Society, 2014). Findings from a meta-analysis which
24

reviewed the association between cervical cancer and oral contraceptives (OC) show an
increased risk of cancer with increased duration of OC use (Muñoz et al., 2006). The results of
the analysis indicated that women with ten years use of OC were twice as likely to develop
cervical cancer compared to those who had never used OCs (American Cancer Society, 2014;
Muñoz et al., 2006). The hypothesized route through which OCs increase risk is interactions
between the hormones and the hormone-receptors in the viral genome (American Cancer
Society, 2014; Muñoz et al., 2006). As a result of disruption of the cervical cells during
pregnancy and child birth, and hormonal interactions, women with a high number of full-term
pregnancies may have an increased exposure to HPV (American Cancer Society, 2014; Muñoz et
al., 2006). Women with suppressed immune systems such as those with AIDS, or those taking
drugs to suppress their immunity, have less capability to fight off HPV infections and are thus at
higher risk for cervical cancer (American Cancer Society, 2014). Poverty is also associated with
increased risk, as women of low income are less likely to be able to afford and access preventive
services (American Cancer Society, 2014). Other factors that have shown some association with
increased risk for cervical cancer incidence are: chlamydia infection, obesity, diet and nutrition,
and previous family history of cervical cancer (Pierce Campbell, Menezes, Paskett, & Giuliano,
2012; US Preventive Services Task Force, 2012).
Prevention. Primary prevention of cervical cancer can be achieved by avoiding exposure
to HPV and/or preventing HPV infection through receipt of the HPV vaccine (American Cancer
Society, 2014; CDC-Centers For Disease Control and Prevention, 2014) Progression of precancerous cells to invasive tumor can also be prevented through regular screening and early
detection. The U.S. Preventive Services Task Force (USPSTF) recommends that women between
the ages of 21 and 65 years receive a pap smear every three years and that women between the
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ages of 30 and 65 years receive HPV testing every five years (US Preventive Services Task
Force, 2012).
Disparities. Since the development and promotion of pap tests and other secondary
preventive measures (HPV vaccine and testing), rates of cervical cancer incidence and
prevalence across the country have declined by more than 75% (Pierce Campbell et al., 2012).
However, this decline has not been equally observed across all populations, and disparities in
incidence and mortality persist across certain racial/ethnic groups and geographic regions (Pierce
Campbell et al., 2012; Rauh-Hain et al., 2013). Over 60% of cervical cancer cases occur among
women of disadvantaged communities (Pierce Campbell et al., 2012). Recent cancer surveillance
data show that the age-adjusted incidence rate is highest among Hispanic women (9.2/100,000),
followed by Black women (9.0/100,000), compared to the average rate of 7.2/100,000 persons
(CDC-Centers For Disease Control and Prevention, 2017). Mortality rates1 also show similar
patterns, with highest rates amongst Black (3.9/100,000) and Hispanic women (2.5/100,000)
(CDC-Centers For Disease Control and Prevention, 2017).
Regional disparities in cervical cancer incidence and mortality also exist across the
country. Women in communities along the U.S.-Mexico border, in the Southern parts of the U.S.
and in the Appalachian region have disproportionately higher diagnostic and death rates (Pierce
Campbell et al., 2012). Surveillance data indicate that white women living in Appalachian
regions have higher rates than white women in non-Appalachian regions (Pierce Campbell et al.,
2012; Reiter, Fisher, et al., 2013; Reiter et al., 2012). Data from 2008 showed that seven out of
13 Appalachian regions had higher mortality rates than the national average, six of the seven of

1

Corrected age-adjusted mortality rate was 10.1/100,000 for black women and 4.7/100,000 for white women
(without regard for Hispanic ethnicity) (Beavis, Gravitt, & Rositch, 2017).
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which are Southern Appalachian sub-regions (Blackley et al., 2012). This disparity also exists by
state, with a majority of Southern states experiencing higher incidence and mortality than the
national rates. One such state is Tennessee with an age-adjusted incidence rate of 8.9/100,000
women compared to a national average of 7.2 and an age-adjusted mortality rate of 2.8/100,000
women compared to the average rate of 2.3/100,000 women (CDC-Centers For Disease Control
and Prevention, 2017).
Appalachia
In 1965, federal legislation officially designated the Appalachian regions, with
subsequent counties added through the years. Currently, Appalachia is a 13-state, 420-county
region that spans across 200,000 square miles from southern New York through northern
Mississippi (Blackley et al., 2012; Reiter et al., 2012) (Figure 3). With an estimated population
of 25 million, the region makes up about 8% of the U.S. population and about one-quarter of the
total population of the 13 states.

Figure 3: Map of the Appalachian Region. Reprinted from Maps- Appalachian Regional Commission.
Retrieved February 2017 from https://www.arc.gov/maps. Copyright 2017 by The Appalachian Regional
Commission. Reprinted with permission
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Rurality. Over a third of Appalachian counties are classified as rural, in that they are
characterized by low population density, geographic isolation and having low economic
resources (Behringer & Friedell, 2006). Rural areas across the country and within the region are
often correlated with high poverty rates, low educational attainment, and low income (Behringer
& Friedell, 2006; Blackley et al., 2012). Based on geographic isolation and limited resources,
rural areas such as those in Appalachia, also have sparse health infrastructure and health care
facilities and limited accessibility to facilities in urban areas.
Education. Evidence indicates the existence of an inverse relationship between
educational attainment and health outcomes; the lower the education level, the higher the
likelihood of negative health outcomes (Robert Wood Johnson Foundation, 2009). The
Appalachian region has historically achieved lower than average high school graduation rates
(Appalachian Regional Commission, 2014). Lower educational attainment is correlated with
higher unemployment, lower income and low literacy levels (Robert Wood Johnson Foundation,
2009).
Income. The association between lower income and negative health status is so evident
that poverty has been termed a ‘carcinogen’(Brodish, Massing, & Tyroler, 2000; Ward et al.,
2004). Low income individuals face issues of healthcare affordability, insufficient health
insurance coverage, and lower accessibility to health care information and resources, and as
such, are more likely to engage in unhealthy behavior and less likely to utilize preventive
services (Behringer & Friedell, 2006; Blackley et al., 2012; Hopenhayn, King, Christian, Huang,
& Christian, 2008). Appalachian poverty rates are about 11% higher than the national average
(Appalachian Regional Commission, 2014).
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Economic Status Designation. Using an index-based county classification system, the
Appalachian Regional Commission (ARC) identifies and monitors the economic status of
counties within the region. This system compares each county’s economic indicators (3-year
average unemployment rate, average income and poverty rate) with the national averages, and
then ranks them based on the aggregate index (Appalachian Regional Commission, 2014).

Figure 4: Map of Counties in Appalachian Tennessee. Map of the Appalachian Region. Reprinted from
Maps- Appalachian Regional Commission. Retrieved February 2017 from https://www.arc.gov/maps.
Copyright 2017 by The Appalachian Regional Commission. Reprinted with permission.

There are five existing designations for economic status: Distressed (counties with at
least two times the national poverty rate and average unemployment rate, and per capita income
at 67% of the national average), At risk (counties with at least 125% unemployment and poverty
rates, and per capita income of at most 67% of national average), Transitional (counties that have
worse status than the national average but do not meet criteria for ‘at-risk’ or ‘distressed’
designations), Competitive (counties with unemployment and poverty rates that are at least equal
to the national average, and per capita income of 80% or more than the national average), and
Attainment (counties with economic indicators that are at least equal to the national average)
(Appalachian Regional Commission, 2014). Only six Appalachian counties have reached the
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attainment status. Counties in Tennessee fall within either of the distressed, at-risk, or
transitional status.
Cultural Identity. Appalachia possesses a distinct cultural identity with family as the soul
of the community and a key source of information (Blackley et al., 2012; Hutson et al., 2011b;
Krieger et al., 2013). A large proportion of the region comprises the ‘Bible-belt’ which consists
of some of the most religious and politically conservative groups in the country (Reiter et al.,
2012). Within the family and community structure, there are deep-rooted perceptions of gender
roles with females assuming major responsibility as caretakers of the family, often placing this
role as a higher priority over caring for themselves (Blackley et al., 2012; Krieger et al., 2013).
Some studies also report residents’ objection to the term ‘Appalachia,’ indicating that it denotes
a derogatory and negative stereotype to their actual attitudes and beliefs (Behringer & Friedell,
2006; Hutson et al., 2011b).
HPV-Cancer Burden in Appalachia. Based on the low socioeconomic profile and
geographic isolation of rural Appalachia, many women in the region experience low literacy, low
income, and inaccessibility to health services that predispose them to negative health status and
outcomes. This issue is evident in the disproportionate burden of cervical and other HPV-related
cancers. Reiter et al. (2013) conducted a study to assess the prevalence of HPV-related cancers in
three Appalachian regions (Kentucky, Ohio and West Virginia) and found that the age-adjusted
incidence of HPV-related cancers was higher in the Appalachian regions of these states
compared to their non-Appalachian counterparts (Reiter, Fisher, et al., 2013). These findings
strongly suggest that preventing HPV infections among this population is a priority for public
health.
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HPV Vaccine
To address the burden of HPV-related diseases and cancers, three vaccines have been
licensed and recommended for routine vaccination. In 2006, the U.S Food and Drug
Administration (FDA) licensed the first prophylactic HPV vaccine. This quadrivalent vaccine,
Gardasil (Merck & Co., Inc.), prevents against four types of anogenital HPV: 6, 11, 16 and 18,
which are established causal factors for genital warts and cervical cancers. In 2009, a bivalent
vaccine, Cervarix, was developed by GlaxoSmithKline to protect against HPV16 and 18. Most
recently, in 2014, a 9-valent vaccine was licensed to prevent against the four types covered by
the quadrivalent vaccine and five additional types: HPV31, 33, 45, 52, and 58 (CDC-Centers For
Disease Control and Prevention, 2015). These vaccines protect against 7 out of 12 of the HPV
types classified by IARC as carcinogens (Bzhalava et al., 2013; International Agency for
Research on Cancer, 2012).
The Advisory Committee on Immunization Practices (ACIP) recommends routine HPV
vaccination for males and females beginning at 11 or 12 years. The 3-dose2 vaccine series can be
started at age 9 and should be completed either one or two, and six months after the first dose.
The vaccine can also be received by females between the ages of 13 and 26 who have not started
or completed their dose, and by males through the age of 21. The vaccines have close to 100%
effectiveness in preventing against their associated HPV types when received before sexual
initiation and exposure to the virus (CDC-Centers For Disease Control and Prevention, 2015;
Saslow et al., 2007). The vaccines have also shown no evidence of adverse effects in clinical

2

Recent updates in ACIP recommendations: For persons initiating vaccination before their 15th birthday, the
recommended immunization schedule is 2 doses of HPV vaccine. The second dose should be administered 6–12
months after the first dose (Meites, Kempe, & Markowitz, 2016).
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trials to evaluate safety (CDC-Centers For Disease Control and Prevention, 2015; Saslow et al.,
2007).
The earliest age recommended for vaccine initiation is 9 years old. This is largely
because it represents the lowest age limit for inclusion in clinical trials, and as such, the vaccine
could not be tested among younger age groups. The recommended age for vaccination is
particularly important as vaccine effectiveness is optimized if administered before sexual
initiation or shortly after. Based on the prophylactic nature of the vaccine, risk of infection was
estimated using adolescents’ age at sexual initiation (Saslow et al., 2007). According to
nationally-representative survey data, 1 out of 4 females in the U.S. reports being sexually active
by 15 years, 4 out of 10 by age 16, and 7 out of 10 by age 18 (Saslow et al., 2007). Risk of
infection is also estimated based on probability of exposure because HPV infection occurs within
a few years of sexual initiation. One study of college-aged women found that 39% of the study
participants had an HPV infection within 2 years of sexual engagement, and another study of
adolescents (13-21 years) showed that 70% of participants had an infection within 5-7 years from
sexual initiation (Saslow et al., 2007).
Barriers to prevention . Despite the evident necessity and effectiveness of the HPV
vaccine, vaccination rates across the country remain sub-optimal, especially among populations
at highest risk for cervical cancer (Holman et al., 2014; Reiter et al., 2012).This suggests that
there are factors that impede access to and/or acceptability of the vaccine. Research indicates that
challenges within the healthcare system and personal and social attitudes about health are
potential barriers to vaccine uptake among women and girls in Appalachia.
A systematic review on barriers to HPV vaccination among U.S. adolescents found that
health care professionals often cited parental financial constraints and attitudes towards the
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vaccine as barriers to recommending and providing the vaccine. Parents cited low knowledge
and awareness, concerns that giving the vaccine was license for promiscuity, low perceived risk
for adolescent’s HPV infection, and perception of vaccine disapproval within their social circles
as barriers to prevention (Holman et al., 2014). A review of the National Immunization Teen
survey data (NIS-teen) reviewing barriers and intentions for vaccination in Appalachian regions
found that parents were resistant to the HPV vaccine for a variety of reasons. A number of
parents felt that the recommended age for vaccination was too young, some felt that the vaccine
was not relevant for their daughter, others cited their daughters’ sexually naiveté as reason for
vaccine irrelevance (Reiter, Katz, et al., 2013). Parents whose healthcare providers had not
recommended or had discouraged the vaccine were also more resistant to the vaccine.
Additionally, some parents reported low awareness and knowledge about HPV and the vaccine,
and concern about the cost of the vaccine as barriers to accepting the vaccine for their daughters
(Reiter, Katz, et al., 2013).
A qualitative study among providers, parents, community leaders and adolescents in
Appalachian Ohio revealed similar themes (Katz et al., n.d.). Within the healthcare system, cost
of the vaccine, low access to healthcare, lack of health insurance, and poor provider-patient
communication were cited as barriers to vaccine uptake. From an individual perspective, fear of
short- and long-term side effects that would affect fertility, cause other illness, or increase
promiscuity were indicated as barriers, as were low knowledge and awareness. Within the social
and cultural context, fear that vaccine uptake could lead to judgment and gossip, and perceived
conflict of the vaccine’s objectives with religious beliefs were cited as additional barriers. These
cultural barriers were corroborated by findings from another study that investigated
communication barriers within the Appalachian culture and found that advertising skepticism
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and fear of reproductive health side effects were common barriers to vaccine uptake (Hutson et
al., 2011b).
Communication, Culture, and Health
Culture is the multidimensional, ecological system in which a community exists, and
consists of a collection of beliefs and values shaped by varying responses to the social,
geographic, political and religious environments. Cultural values, in turn, shape a community’s
attitudes towards health, health behaviors, and the concept of cancer (Kagawa-Singer, Dadia, Yu,
& Surbone, 2010). While the concept of culture is often applied to immigrant and ethnic groups,
it is important to note that every community has an underlying theme through which they view
and interpret their daily experiences. While many studies on health disparities have established
the role of social and economic determinants of health (e.g., education, income, geography, etc.),
the role of culture is often overlooked. At the core of every community is this salient determinant
of health that influences how we interpret health practices, determines the social structures
within families, and provides a blueprint for community relations.
Scholars suggest that the core of the rural Appalachian culture is rooted in the distinctive
interaction between geographic isolation and economic depravity which may have led families
and communities to exclusively depend on each other and form close knit ties (Hutson, Dorgan,
Phillips, & Behringer, 2007b). The theory is that these ties have fostered a culture of storytelling
through which issues, including information on health and wellness, are disseminated (Hutson et
al., 2007b). As a result of this communication mechanism, negative individual perceptions about
the healthcare system, health behavior, sexual health, and cancer in particular are often projected
onto family members, individuals within their social networks and the larger community
(Vanderpool et al., 2015). In the absence of any individual perceptions or experiences, little
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information is disseminated and low levels of knowledge are perpetuated within the community
(Hutson et al., 2011a, 2007b).
This communication culture is evidenced in the case of HPV and cervical cancer
communication in rural Appalachia where healthcare providers often do not talk to their patients
about HPV, the vaccine or cervical cancer (Hutson et al., 2011a; Krieger et al., 2012; Roberto et
al., 2011). Thus, the foundational knowledge on these health issues is limited. Based on its
associated stigma, sexual health issues are often not a topic of discussion within family and
community networks. This limited dialogue on HPV and the vaccine has led to the perpetuation
of ‘spheres of silence’ within rural Appalachian communities (Hutson et al., 2011a). However,
the propagation of information from anti-vaccine messaging, which often cite vaccine side
effects and the reasoning that it encourages promiscuity, is more likely to dominate an
Appalachian woman’s perceptions and shape her attitudes towards the vaccine (Hutson et al.,
2011a; Krieger et al., 2013).
Providers’ influence on HPV Vaccine Acceptance
Receiving a recommendation from a healthcare provider is an important predictor of
HPV vaccine uptake (Kahn et al., 2007; Reiter, Katz, et al., 2013; Roberto et al., 2011).
Providers both directly impact vaccine uptake, as their attitudes influence parental willingness to
accept the vaccine for their daughters, and indirectly, as it determines the level and quality of
available vaccine information within a rural community. It is therefore of particular concern that
pediatricians in Appalachian regions are less likely to recommend the vaccine compared to their
non-Appalachian counterparts. Reasons for low recommendation ranged from low perceived
susceptibility of their patients to concern about negative parental attitudes due to social and
cultural implication and cost of the vaccine (Kahn et al., 2007; Krieger et al., 2012). Despite
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these findings, we do not have extensive knowledge on the factors that influence vaccine
recommendation among a wider range of health care providers (i.e., nurse practitioners, primary
care physicians, gynecologists, and pediatricians), particularly in rural Appalachia.
Maternal Influences
Mothers play a central role in the health of their families, especially in their daughter’s
health. Not only are girls more likely to communicate with their mothers than their fathers about
their sexual health, but their personal attitudes towards the vaccine are also influenced by
maternal endorsement (Roberto, Krieger, & Katz, 2014). This is also true in Appalachia where
mothers are often the gatekeepers of the family’s health and wellbeing and a key source of health
information (Krieger et al., 2013).
Mothers are an important source of psychosocial (endorsement) and instrumental
(financial) support in young women’s vaccine uptake, and they serve as the primary decisionmakers on adolescents’ HPV vaccine receipt (Gilkey & Mcree, 2016; Krieger et al., 2011).
Maternal endorsement of the vaccine, and willingness and ability to pay for the associated costs
significantly impact their daughter’s vaccine uptake (Krieger et al., 2011). Krieger et al. (2011)
conducted a study among mother-daughter dyads in a Midwestern U.S. university and found that
daughters who reported discussing the vaccine with their mothers were nine times more likely to
have received the vaccine compared to those who had not. The results indicated that a mother’s
intention to encourage their daughters to talk to their physician about the vaccine was associated
with the daughter’s report of maternal HPV communication and receipt of the vaccine.
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CHAPTER 3
METHODS
Introduction
The bulk of the proposed study methodology (design, participant recruitment, and
measures) has been implemented in previous HPV vaccine studies among healthcare providers,
mothers and adolescents. However, since most of these studies were conducted before
widespread availability of the three vaccines and among different populations (not including
rural Appalachia), the study elements were modified to suit the proposed aims of this study as
well as the study population. Prior to data collection, all elements of the study were reviewed and
approved by the university’s institutional review board (IRB).
Design
This study utilized a mixed-methods approach to explore factors associated with HPV
vaccine acceptance and self-reported vaccine uptake in Appalachian Tennessee. Semi-structured
interviews and focus groups were conducted to gain in-depth views on important individual and
contextual factors. These qualitative methods provided richer and deeper insights into the
attitudes and beliefs associated with HPV vaccine acceptance. Quantitative methodologies were
implemented to measure associations, frequencies and trends in vaccination status based on
collated data from the completed surveys. Findings from both arms of the study were then
triangulated to identify diverging and converging themes across the triad.
Study Setting and Participants
Semi-structured Interviews: Using a purposive sampling strategy to ensure adequate
representation by gender, practice setting (clinic, hospital, academic-affiliated), and ARC
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economic status designation of the county of practice (distressed, at-risk, transitional)3,
healthcare providers were recruited from Washington, Sullivan, and Unicoi counties in Northeast
Tennessee. The investigator identified prospective participants through her social and
professional networks and by reviewing listed resources of health services information in these
counties. To be eligible for the study, the interview participant had to be a healthcare provider,
practicing in one of the aforementioned counties, and administering vaccines as part of their
clinical practice. Recruitment letters (Appendix A) were sent by email to eligible healthcare
providers, and then follow-up contacts were made by phone, if necessary. A total of 12
healthcare professionals were interviewed between November 2016 and January 2017 (Table 1).
This sample of 12 healthcare professionals included three key informants who were initially
interviewed to provide first-hand knowledge about health services in the community and to pilot
test the proposed interview questions for comprehension and relevance. The remaining nine
healthcare providers were then subsequently interviewed using the finalized question guide.
Focus Groups: A recruitment letter (Appendix B) was disseminated via email to faculty and staff
at East Tennessee State University. Mothers with at least one daughter between the ages of 11
and 26 years were invited to participate in a focus group. This convenience sample provided
access to eligible participants who potentially lived in diverse communities, reflective of
different county ARC designations. To ensure that the study also included participants from
more distant communities which may not be represented in the campus population, eligible
mothers were also recruited from Hancock County, TN. Interested women who read the
recruitment material completed an eligibility screener (Appendix C), read the consent document,

3

Since Appalachian Tennessee falls within Central and South-Central Appalachian which is classified as rural, it
would be redundant to group counties using rural-urban continuum. Hence, the study will utilize ARC-economic
status designation for county economic index classifications.
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and signed up for a convenient time slot. Two focus groups (n=13) were conducted between
November and December 2016 (Table 2).
Survey: The study employed a cross-sectional design to recruit a convenience sample of female
students from East Tennessee State University. Students were recruited using the Department of
Psychology’s online research participation site (Sona systems), and eligibility was limited to
female students who were at least 18 years old at the time of survey completion. All females
regardless of vaccination status were eligible for study participation. The survey was
administered over a 3-month period from October to December 2016.
Data Collection
Qualitative. During each scheduled interview session, participants signed informed
consent documents (Appendix D) and completed a 6-item, paper-based questionnaire assessing
demographic and practice characteristics (Appendix E). Using a semi-structured guide, the
interview explored providers’ perceptions of vaccine acceptance both from the patient and
practice perspective and their attitudes towards the vaccine (Appendix F). The sessions were
conducted at convenient and private locations, chosen by the providers (clinic office = 9, church
office = 1, home = 1), with an average duration of 35 minutes. Provider participation was
voluntary with no expected compensation.
Eligible women were invited to participate in a focus group to share their opinions and
experiences with the HPV vaccine. The focus group with the campus participants was held at a
central location on the university campus, conducted at lunchtime during the work week. During
the scheduled session, participants signed informed consent documents (Appendix D) and
completed a short survey assessing demographic characteristics, daughter’s vaccination status,
family history of cervical cancer, and vaccine recommendation from their healthcare provider
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(Appendix G). The community session was held at the Hancock County Art Center and
conducted in the evening after the work day. Each focus group session lasted approximately 60
minutes, and light meals were provided as compensation for participants’ time. The interviews
and focus group sessions were audio-recorded and then transcribed verbatim by a CITI-trained
research assistant.
Quantitative. Prior to survey completion, participants were required to read and consent
to study participation. The online surveys were completed outside of class periods, at any
convenient time and place chosen by the participants, and lasted an average of 30 minutes. The
questionnaire was administered through Survey Monkey, and the link to access the survey was
made available through the Sona system. University students with access to the Sona system who
met the inclusion criteria and completed the survey received course credit as compensation for
their time. The survey started with a brief eligibility screener to determine gender and age and
progressed with general demographic questions and constructs related to reproductive health and
vaccine acceptance (Appendix I). A total of 479 valid responses were collected during the 3month study period.
Measures
Research Aim I
To explore HPV vaccine attitudes and perceptions among a diverse sample of healthcare
providers in Appalachian Tennessee.
The semi-structured interviews followed an open-ended question guide (Appendix F) and
began with general questions about the provider’s role in the practice, clinic characteristics, and
their overall experience with the HPV vaccine. The session then progressed with questions that
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explored providers’ perceptions about parental vaccine acceptance and associated factors
(barriers and concerns) and more in-depth exploration to assess providers’ attitudes towards the
vaccine. The investigator probed participants’ responses to gain insight into the cultural and
moral values that may influence their conceptualization of the vaccine and how it is subsequently
framed to patients and parents.
Research Aim II
To explore attitudes, perceptions, knowledge and awareness related to the HPV vaccine
among Appalachian mothers.
Similar to the interview, the focus group sessions employed a semi-structured, openended guide that began with general questions about participants’ children (number of children,
gender and ages). Participants were then asked to discuss their feelings about vaccines in general.
As each session progressed, participants were asked about their: knowledge and feelings about
the HPV vaccine, cervical cancer, community’s perception of cervical cancer risk and the HPV
vaccine, the nature (content and relationship) of communication with their daughters and
healthcare providers, and sources of health information. Elicited responses were probed to assess
participants’ cultural values, perception of gender roles, and moral values that may influence
their attitudes towards the vaccine.
Research Aim III
To measure self-reported vaccination rates and assess attitudes, perceptions, knowledge and
awareness related to the HPV vaccine among a sample of young women who fall within the
recommended age range (≤26 years) for vaccine dose completion.
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The survey contained questions on demographics, region of residence, vaccination status,
sexual initiation and period of vaccination, attitudes and perceptions about HPV and the vaccine,
knowledge and awareness about HPV, cervical cancer knowledge and awareness, motherdaughter communication, and perceptions of maternal vaccine endorsement (Appendix I).
Perceptions of Gender Roles. Using questions culled from the adolescent version of the
Attitudes toward Women Scale (AWS) developed by Spence and Helmreich,(King, Phillips,
Walker, & O’Toole S, 2014) respondents’ perceptions of the rights and roles of women in
professional and marital relationships and in dating dynamics were assessed. These measures
have been previously evaluated and have shown high internal (Cronbach’s α= 0.85) and testretest reliability (r = 0.81-0.86; p<0.05) (Daugherty & Dambrot, 1986; King et al., 2014) Using
a10-item scale adapted for this study, participants were asked to indicate their level of agreement
with different statements (e.g., ‘Women who carry condoms are easy’, ‘The father should have
greater authority than the mother when raising children.’) on a 5-point Likert-type scale ranging
from ‘strongly disagree’ to ‘strongly agree’.
Cervical Cancer Knowledge and Perceptions. Knowledge and awareness of cervical
cancer was measured using items from the National Cancer Institute’s 2013 Health Information
National Trends Survey (HINTS) questionnaire. Participants’ knowledge about the causes of
cervical cancer and prevention strategies was tested using short multiple-choice questions. Their
attitudes towards cervical cancer, specifically, and cancer in general were assessed based on
their: perceptions of developing cancer, cancer beliefs (fatality, severity, preventability), and
faith beliefs (‘faith will help me prevent the disease’); each response was rated on a 5-point
Likert-type agreement scale. These measures were adapted from the HINTS survey and were
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previously used in a study evaluating cancer risk perceptions and beliefs in the Appalachian
region (Vanderpool & Huang, 2010).
HPV Knowledge and Awareness. To measure participants’ knowledge and awareness of
HPV, items were adapted from the CDC’s Youth Risk Behavior Surveillance (YRBS)
questionnaire and the HINTS item on HPV awareness and sources of information. Participants
answered a series of multiple-choice and true/false items to indicate their awareness of the
vaccine, source of information, modes of transmission, expected prognosis (e.g., HPV can
cause…? HPV can go away without any treatment), and methods of prevention.
Self-Reported Vaccination Status. Participants were asked to report their HPV
vaccination status (“Have you received the HPV vaccine?”), and how many doses had been
completed. Responses were recoded as dichotomous variables, ‘vaccinated’ for those who had
started or completed the dose and ‘not vaccinated’ for those who had not initiated the vaccine
series. This item was adapted from the CDC’s National Immunization Survey-Teen, which is
used to collect annual data on national and state level vaccination coverage. To directly measure
individual susceptibility to HPV infection, the survey also asked about age of vaccine receipt and
timeframe of vaccine receipt relative to sexual initiation (‘Which occurred first-your first sexual
intercourse or your first HPV vaccine shot’?).
Perceptions towards HPV and the Vaccine. Using a 5-point Likert-type scale, the survey
assessed participants’ perceptions towards both the virus and the vaccine. These items measured
susceptibility to HPV infections (‘I can get HPV’), vaccine effectiveness (‘The vaccine cannot
really prevent HPV’) and worry about side effects from the vaccine (‘I am worried about side
effects from the vaccine’).
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Perceived control. The survey assessed participants’ perceived control over their decision
to receive the HPV vaccine based on their response choices to three items (‘For me to receive the
HPV vaccine is easy’, ‘The decision to receive the vaccine is beyond my control’, ‘Whether I get
vaccinated is not entirely up to me’) on a 5-point Likert-type agreement scale. Participants were
also asked to indicate how much they agreed with statements developed to assess their
perceptions of vaccine acceptance within their interpersonal networks. These measures were
developed for the purpose of this study based on literature on the application of theories in
depicting health behavior (Montaño & Kasprzyk, 2008).
Research Aim IV
To explore associations between mother-daughter sexual health communication and self-reported
vaccine uptake in Appalachian Tennessee.
The survey asked true/false questions to evaluate content of mother-daughter
communication on sexual health, HPV, preventive health behavior, and cervical cancer. To
investigate subjective norms, the study also asked participants’ to indicate their perceptions of
their mother’s endorsement of the HPV vaccine.
Maternal Endorsement. To assess the influence of maternal approval on vaccine
acceptance among this sample of college women, we asked respondents to indicate their level of
agreement, on a 5-point Likert-type scale, to three statements: ‘My mother thinks I should
receive the HPV vaccine’, ‘My mother thinks it would be a good idea to receive the HPV
vaccine’, ’My mother wants me to get the HPV vaccine.’ These items are similar to the measures
for normative perceptions and were also developed for this study based on existing literature on
the application of health behavior theoretical models (Montaño & Kasprzyk, 2008).
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Mother-Daughter Communication. Study participants were asked to respond to questions
assessing the content and nature of sexual health communication with their mothers. Participants
first answered true or false to whether or not their mother had discussed a range of 11 sexual and
reproductive health topics (e.g., safe sex practices, birth control, STI/STDs, etc.) with them.
They were then subsequently asked to indicate agreement, on a 5-point Likert-type agreement
scale, their reception (‘I was receptive when my mother and I talked about’…) when these topics
were discussed. Lastly, to explore mother-daughter relationships, participants were asked to
indicate their level of agreement with a 20-item scale designed to assess parent-adolescent
communication (Barnes & Olson, 1985).
Appalachian Identity. To assess cultural identity, study participants (interview, focus
group and survey) were asked to indicate whether they identified as Appalachian (‘Do you
identify as Appalachian?’). This item was included to assess both demographic and cultural
characteristics and was of particular interest considering the study’s aim to explore HPV vaccine
acceptance in Appalachian Tennessee.
Data Analysis
Qualitative Analysis. Audio recordings from the interviews and focus groups were
transcribed verbatim and then read in their entirety to gain familiarity with the data corpus. Each
data corpus was then analyzed following an inductive thematic approach (Boyatzis, 1998; Braun
& Clarke, 2006). Utilizing a hybrid of inductive and a priori methods, the principal investigator
(PI) employed structural coding techniques to develop a coding scheme, labeling and
categorizing participants’ responses that were relevant to the research aims. The collated codes
were further analyzed by grouping similar codes and data extracts into potential thematic
categories. Each category was reviewed and refined to ensure internal homogeneity within each
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theme and external heterogeneity with the others (Braun & Clarke, 2006). Central and recurring
themes were highlighted and then explored to identify and depict patterns of association. Finally,
collated themes were compared across the interview and focus group sessions in order to identify
differences and generate the most representative overlapping themes.
Quantitative Analysis. Collated survey responses were reviewed to check for
completeness, outliers and distribution. Statistical analysis was limited to complete survey
responses from participants between the ages of 18 to 26 years old (n=479). Descriptive statistics
were calculated for both dependent and independent variables. The dependent variable was
vaccine status based on self-report, measured on a dichotomous scale. Participants who reported
receiving at least one dose of the vaccine were classified as vaccinated, and those who had not
received any dose were classified as unvaccinated. The independent variables measured include:
demographic characteristics, region of residence, attitudes and perceptions about HPV and the
vaccine, knowledge and awareness about HPV, cervical cancer knowledge and awareness,
mother-daughter communication, and perceptions of maternal vaccine endorsement.
Young women who reported they had been vaccinated were compared to those who had
not been vaccinated. Categorical variables were compared using Chi-square tests, and continuous
variables that showed normal distribution were compared using t-tests. For Likert-type scale
items, the PI conducted tests of normality (Kolmogorov-Smirnov; Shapiro-Wilk); items with
non-normal distributions were then put through a series of dimension-reduction and reliability
tests, before comparing means using a Mann-Whitney test. Independent variables with
significant univariate results were then plotted in a multivariate logistic regression model to
explore their association with vaccine status, while also controlling for confounding.
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Significance of association was determined based on a p-value of ≤ 0.05. Quantitative data were
analyzed using SPSS (IBM SPSS Statistics version 23.0).
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CHAPTER 4
RESULTS
Research Aim I. To explore HPV vaccine-related attitudes and perceptions of a sample of
healthcare providers in Appalachian Tennessee.
Of the 22 health care providers invited to participate in the study, 12 consented and
participated in a 30-minute interview session. Participants were predominantly female (n=10),
two-thirds held nursing degrees, and the others held medical degrees. About 60% identified as
Appalachian, and all of the practicing providers reported that they often recommended the
vaccine (Table 1).
Table 1: Demographic Characteristics of Healthcare Providers

Gender

Characteristics
Male
Female

N (%)
2 (16.7)
10 (83.3)

County of practice

Washington1
Sullivan1
Unicoi1

8 (66.7)
3 (25)
1 (8.3)

Clinical degree

RN
BSN
MSN
MD

3 (25)
3 (25)
2 (16.7)
4 (33.3)

Years in Practice

>5
5-10
10-15
≥20

1 (8.3)
2 (16.7)
3 (25)
6 (50)

Practice Setting

Academic
Clinic
Health department
Faith-community

4 (33.3)
3 (25)
4 (33.3)
1 (16.7)

Yes
No

7 (58.3)
5 (41.7)

Appalachian Identity
1County

ARC-Economic status designation: 1Transitional, 2At-risk, 3Distressed
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Thematic analysis revealed themes in providers’ attitudes towards the vaccine and their
perceptions of the vaccine’s acceptance among patients and in the community. The themes
around patients’ perceptions predominantly focused on parent perspectives, not the adolescent
and young adult perspectives as the vaccine recipients.
Provider Attitudes. Overall, this sample of providers indicated positive attitudes towards
the vaccine. Most of the providers felt that there was solid scientific evidence to endorse the
vaccine: “I’ve read reasonably much about it and it appears to be perfectly safe and very
effective. Very effective, I mean we’re starting to see the studies now…and you know they were a
little bit reluctant to talk about what kind of cancer reductions they could claim because nobody
had really gone that far yet, but now we’re starting to see some of that data back and it’s pretty
impressive.” None of the providers explicitly cited resistance towards the vaccine, however upon
further probe, a few providers indicated concern about the vaccine. These concerns alluded to the
uncertainty of long-term side effects, the multiple dose schedule and the subsequent need for
follow-up, and the vaccine’s potential impact on cervical cancer screening rates: “The only
concern I think I would have is that it could potentially make people think they don’t need PAPs
and once you know, I think it would be easy for people to make that connection like well this is
supposed to protect me against the thing that PAP smears test me for so now I don’t need
PAPs.”
While all of the interviewed providers indicated that they often recommend the vaccine,
the way in which the recommendation was framed provided additional insight into their attitudes
towards the vaccine. Most of the providers reported referring to the vaccine administration
schedule or the CDC’s recommendation guidelines, and only a few indicated that they
emphasized its utility for cervical cancer prevention.
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Barriers in practice. Some of the providers felt that there were factors within their
clinical practice that may inhibit vaccine acceptance. Factors such as the associated costs of
stocking and providing the vaccine and storage logistics could influence patients’ accessibility to
the vaccine. One provider noted, and a few others affirmed, “the funds to keep vaccines
here…there’s a lot of very particular requirements for vaccines. Keeping your refrigerators at a
certain temperature, it’s not going to cut off those types of things.” These barriers were
especially noted by providers practicing in school-based clinics, none of which currently stock
the HPV vaccine. In addition, they raised the issue of the enrollment requirement for the
‘Vaccine for Children (VFC)’ programs, whereby clinics had to complete multiple and daunting
procedures in order to be enrolled with the health department to receive coverage for uninsured
and under-insured patients. Time limitations during clinic consults was also noted as a barrier to
recommending the vaccine, particularly as it relates to educating patients and parents and
alleviating their fears, as one provider mentioned “It can be really rough when you’ve got 15
minutes budgeted for checkup, but you’re going to spend 20 minutes discussing all the vaccines
and you know maybe at the end of it you’ll get mom to let you give one…or maybe they aren’t
going to give any at all.”
Providers also perceived that the lack of school-entry requirement for the vaccine was a
barrier to acceptance, as providers were less likely to proactively recommend it along with other
mandated vaccines such as the MMR vaccine. As one provider stated, “the HPV of course right
now kind of falls through the cracks. It’s not required, it’s recommended.” There was the
perception that the vaccine’s recommendation classification also influences parental beliefs
about the vaccine’s safety, as stated by another provider, “they don’t think the vaccine’s safe
because it’s not required, so therefore it’s not required because it’s not safe.” Additionally,
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patients were more likely to resist the vaccine since it was not required, “If it were required we’d
give it more easily, and I have a feeling if it were required some parents wouldn’t even ask what
it was who might otherwise deny it.”
Perceptions of Vaccine Acceptance. There was a mixed reaction in providers’ experience
with the HPV vaccine. Some providers felt that the vaccine was becoming more acceptable
compared to previous years. As described by one of the clinicians, “I think more and more
people are open to it, I think. I’ve been in the general clinic for about a year and a half, and I’ve
seen the slow shift in people being open to it.” On the flipside, a number of providers felt that
there was low awareness about the vaccine. One provider reported, “some people just
haven’t…don’t know anything about it and therefore they are just hesitant to get it.” This
perception of continuous resistance was echoed by many providers who discussed experiencing
parents’ hesitation when they introduced the vaccine for their daughters, “my experience has
been, that’s the one that’s most likely to be refused.” In conceptualizing the perceived hesitation
among patients, one provider succinctly categorized the vaccine as “the colonoscopy of vaccines,
it’s colonoscopies with prevented recommendation that’s most likely refused.”
Perceived barriers for patients. The predominant theme mentioned by a number of the
providers was misinformation among patients as the main barrier to vaccine acceptance: “really
the biggest barrier is just misinformation on the patient side. That’s the biggest one.” Providers
felt that the propagation of wrong information had a significant influence on patients’ attitudes
towards the HPV vaccine specifically, and the ‘anti-vaccine’ movement in general. They also
noted the role of the internet and social media in enabling this barrier, as one respondent stated:
“…with HPV just seems to be that there’s stuff out there on the internet that’s keeping parents
from accepting it.”
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In further discussing their perception of potential barriers which may hinder patients’
acceptance of the vaccine, vaccine affordability and availability, and the need for follow-up
visits to complete the vaccine series were some of the predominant themes discussed by most of
the providers. The issue of the vaccine’s affordability as it relates to cost: “Cost is an issue
especially when it was new because you know if we were talking about getting the vaccine, a
really early question would be does my insurance cover it?,” and insurance coverage: “so some
of the barriers we have are on insurance coverage…” were other points cited. Unavailability of
the vaccine at the time of recommendation or discussion was another potential barrier discussed:
“if we don’t physically have the vaccine and we have to write a prescription for it, that’s one
more step in the process and a lot of times patients won’t take the imitative to go to the
pharmacy and get that prescription and then make another appointment and come back and get
the shot.” Several providers identified the multiple-dose schedule of the vaccine as a barrier to
acceptance, this was discussed both in relation to their patient: “I think it’s unfortunate that the
schedule of it is hard to adhere to, having people come back repeatedly I think makes it
challenging to fully vaccinate people, and I think that now there’s that recognition that maybe a
two shot series is adequate…so that’s better than three, still not as good as you know one shot
all done,” and from their perspective as patients, “I feel like I can speak from experience, I’ve
talked to patients ‘cause I got 2 out of 3, I never went back and got the third for no good reason
other than I was busy.” This barrier was further illustrated by another provider: “I have a
daughter who is a pharmacist that absolutely understands everything about HPV and she has an
eleven-year-old and a thirteen-year-old and she’s gotten her first shots and has never followed
up on the rest.” The vaccine’s delivery mechanism as a ‘shot’ was also discussed by multiple
providers as a potential barrier for the actual vaccine recipients (adolescents and young adults)
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who often relay aversion to pain “there’s just the general fear of needles…nobody, even when I
have kids that are old enough to make their own decisions, often they don’t wanna do it.”
Specific to adolescents’ vaccine acceptance, some providers perceived that dependence
on parental approval could inhibit young women from receiving the vaccine if they were willing
to accept the vaccine but the parents or guardian disapproved. As discussed by one of the
providers, “Let me check with my mom first is a response that I get a lot. I don’t know if it’s their
easy way of saying, ‘I’m not interested,’ or if they really and truly are checking with their mom,
one to find out if insurance covers it or two that mom would approve of them getting the
vaccine.”
Parental beliefs. Respondents perceived fear of side effects as a recurring concern among
parents. One provider noted that “The parents are very worried about is it safe,” and another
provider explained, “I have a friend who has two teenage or pre-teens and I asked, ‘Are you
going to get it’? And she said, “No, there are too many side effects’.” Providers stated that
patients were not always able to provide medical justification for their claims of the vaccine’s
side effects. The novelty of the vaccine was another perceived fear, which also related to parent’s
questioning the vaccine’s safety. One provider stated that, “a lot of parents feel like this is a new
vaccine, even though the vaccine’s been around for several years, they feel like it’s still new, and
therefore may not be safe.” This perception was reaffirmed by other providers who reported they
also received questions about the vaccine’s novelty and safety.
Providers also perceived that parents often considered the necessity of the vaccine for
their children in relation to their age and the vaccine’s implication for sexual activity. Providers
stated that parents often questioned, “Is it necessary for my child?” and subsequently usually
decided to delay vaccine receipt, as explained by a provider, “probably the thing would be that I
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get a lot is we’re not gonna get that today, and then when she’s old enough she can make her
own decisions.” According to providers, the question of necessity was often discussed in relation
to the child’s sexual activity, “the specific resistance to the idea that my child is going to be
sexually active or can be exposed to this, parents really don’t want to think about that when
they’ve got an 11-year-old.” Sexual activity was considered again in terms of parent’s belief of
an implied permission for sexual initiation or promiscuity once the vaccine is received, as
mentioned by one provider, “They think it’s an ‘okay to have sex’ if they get it for their
children.”
Parent’s distrust of the government and pharmaceutical companies was also cited as a
reason for vaccine resistance. A couple of providers noted that some parents believe, “that it’s
just the pharmaceutical companies just trying to make money like there is a distrust”, and “think
that the government puts dangerous stuff in it.” In reaffirming this perception of distrust among
patients, other providers also felt that it was indicative of the emerging resistance towards
vaccines in general, “the anti-vaccine movement,” as it was described by one provider. The
resulting resistance that this movement perpetuates was further explained by another provider
who stated, “I think really the biggest thing is people are suspicious of vaccines in general.”
Lastly, providers believed that the low perceived susceptibility among patients, both
parents and their children, hindered acceptance of the vaccine. One provider explained that this
perception was common among her patients, particularly in relation to sexual health, “So, a lack
of perceived risk which is kind of a common theme in my patient population in particular when it
comes to sexual health.” This perception was re-affirmed by another provider who illustrated the
point by putting it into perspective with polio, another vaccine-preventable disease, “If people
tell you, you need a vaccination for polio… uh in my age group or so people would get a polio
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vaccine right away, but we saw all the risks of it so it wasn’t you know… I mean people did it
because they didn’t want polio and you did it for your children, because you were very worried
about polio. So, to me it’s a matter of whether you perceive it as something that is… um… as
harmful.” Other providers attributed the low perceived risk to be reinforced by low levels of
awareness and education about HPV and the vaccine, “most of the time if they say no it’s because
they haven’t heard of it, they didn’t know about it, occasionally you’ll get people who say, ‘no I
don’t want that,’ but usually they just kind of look at you a little confused like I don’t know what
you’re talking about.”
Community Perception. In discussing their perceptions of vaccine acceptance among
residents of Appalachian Tennessee compared to other communities, a few providers felt that
there were similar levels of acceptance. However, most of the providers felt that there was a
difference in perception, with Appalachian Tennessee exhibiting more resistance compared to
other regions. Some providers perceived that the difference was due to religious conservatism in
the region, as illustrated by one provider, “So I think that we’re in the Bible Belt, and according
to the Bible, we should wait or according to religious… ideology, we should wait until we’re
married to have sex, and so the thought process is, ‘well my kid is not going to have sex before
they are married, so why would they need that vaccine anyway?’” Other providers felt that the
difference was also influenced by the community’s perception of sexual health topics in general.
As explained by a provider, “I think here there’s probably a higher concentration of people who
are really focused on kind of abstinence-only education for their kids…you see a lot of parents
who just are not comfortable with the idea of talking about birth control or STDs or the HPV
vaccine or anything having to do with sex because they just… really wanna drive home to their
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kids that abstinence is the only um you know the only choice. So I think we probably see that a
little more here than in other parts of the country.”
Facilitating Vaccine Acceptance. In addition to sharing their perceptions and experiences,
participants discussed effective strategies they had employed in recommending the vaccine. A
recurrent theme among providers was the idea of reminding parents, in response to hesitation
based on implied sexual activity from the vaccine, of their daughter’s susceptibility to
STIs/STDs, as one provider stated, “I tell parents that y’know, your daughter can be lawfully
wed to one man and have sex with that person only, and still, if he brings the virus into the
marriage, she’s the one that pays the price.” Many of the providers also highlighted the health
department as a resource for receiving the vaccine and other health services and indicated often
referring uninsured or underinsured patients.
Participants were also asked to provide recommendations for how vaccine acceptance can
be improved. Many of the providers emphasized the need to increase education and awareness
about the vaccine and the diseases it prevents. One provider felt that a “national… education
campaign about HPV would probably…work.” Other providers reaffirmed this strategy but
particularly highlighted the need to directly educate adolescents, as noted by one provider,
“educating the kids themselves…education, sex education and things like that, in the schools,
and including that in that conversation, talking about the HPV vaccine…as well as like other
things that they need.” Interestingly, while some providers felt that the church was also a
potential setting to educate youth, one provider noted, “I think church would be a really good
setting because uh if you had a parish nurse for example, you know they’d have a captive
audience as far as the parents and the teenagers.” There was contradictory evidence from faithcommunity practitioners, who felt that most of the congregation sought health information from
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their healthcare providers, “from my perception, I don’t think they would tend to come to the
congregation or the congregational nurse looking for information.”
Participants also recognized and discussed their role as providers in facilitating vaccine
acceptance. According to a respondent, “one of the things that makes a difference in people
getting a vaccine is providers giving a strong recommendation. So rather than saying, ‘hey do
you maybe want to get a shot today?’, saying like, ‘hey I noticed that you are due for this shot,
and we recommend that all of our patients get it because of X, Y, Z,’ and patients are more likely
to get it if you give them kind of a confident recommendation as their provider.” Some providers
also felt that making the recommendations more personal or including scenarios that patients
could relate to would increase acceptance. Additionally, some providers emphasized the need to
highlight the vaccine’s effectiveness in cancer prevention instead of discussing the sex-related
risk. One of the respondents perceived that framing it this way would have yielded a different
reception, “I think if they would have marketed it from day one as a cancer vaccine instead of
even using the word sex, that they would have a different…”
Research Aim II. To assess attitudes, perceptions, knowledge and awareness related to the HPV
vaccine among Appalachian mothers.
During the 3-week period between November and December 2016, three focus groups
were conducted. A total of 13 mothers (mean age= 47.5 years) attended and participated in a
discussion, and shared their opinions and experiences on the HPV vaccine, cervical cancer and
health communication. About two-thirds (n=8) of the participants identified as Appalachian,
over 50% of the participants had at least a college degree, all participants indicated some type of
health insurance coverage, and all were employed (Table 2). About two-thirds (n=8) of mothers
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reported vaccinating their daughters against HPV, six of whom also reported receiving a
provider’s recommendation for the vaccine (Table 3).
Table 2: Demographic Characteristics of Focus Group Participants
(N = 13)
Characteristics

N (%)

County
Carter2
Greene2
Hancock3
Washington1

1 (7.7%)
1 (7.7%)
5 (38.5%)
5 (38.5%)

Yes
No

8 (61.5%)
5 (38.5%)

Married
Divorced

9 (69.2%)
4 (30.8%)

High school diploma/GED
Associate degree
College degree
Graduate degree

1 (7.7%)
2 (15.4%)
3 (23.1%)
7 (53.8%)

Full-time
Part-time

11 (84.6%)
2 (15.4%)

$35,000-$50,000
$50,000-$75,000
≥$75,000

4 (30.8%)
4 (30.8%)
5 (38.5%)

Employer sponsored
Private
Military healthcare
State-Sponsored

9 (69.2%)
2 (15.4%)
1 (7.7%)
1 (7.7%)

Appalachian Identity

Marital Status

Education

Employment

Household income

Health Insurance

County ARC-Economic status designation: 1Transitional, 2At-risk, 3Distressed
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Table 3: Provider Recommendation and Daughter’s Vaccination Status

Provider
Recommendation

Yes
No

Vaccination Status
N (%)
Yes
No

X2 {p-value}

6 (46.2)
2 (15.4)

5.45 (p=0.065)

3 (23.1)
2 (15.4)

Attitudes towards HPV vaccine. Most of the focus group participants had heard of the
vaccine, although their level of awareness varied. The mothers who had heard about the vaccine
reported hearing about it from their healthcare providers or through television advertisements.
Their attitudes towards the vaccine were predominantly positive, and most of the participants
emphasized the protective attributes of the vaccine. Upon being asked to describe the vaccine in
one word, participants’ responses included: “protection,” “safety,” “cancer,” “needed”,
“prevention,” and “benefit.” ‘Protection’ was the primary theme, and it was directed at the
vaccine’s utility in cancer prevention. One mother said, “This is a vaccine that could possibly
prevent my child from having cancer in the future. Why would I not come in here and get this
vaccine?” Many of the mothers felt that receiving the vaccine was standard practice and drew
parallels between the HPV vaccine and other administered vaccines, as illustrated by one mother,
“Well you think and we give them [MMR], we give them chicken pox, and chicken pox is not a
horrible thing to go through. I lived through it, but I give them a vaccine for that so why not give
them a vaccine for something that could very well save their life?” This notion was affirmed by
other participants, one of whom also noted the vaccine’s utility in protecting her daughter against
reproductive health issues resulting from cervical cancer.
Perceptions towards resistance. While many of the participants conveyed positive
attitudes towards the vaccine, both mothers who had their daughters vaccinated and those who
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had not, relayed concerns about the vaccine. The primary factors of concern were: worry about
side effects, the newness of the vaccine, perceived lack of effectiveness, and necessity of the
vaccine at the recommended age (11 to 12 years old). Due to perceived side effects, one mother
relayed regret in vaccinating her daughters, “looking back now … I don’t know if I would
necessarily elect to still have the HPV [vaccine], I don’t know if this has anything to do with
it…but both of my daughters are chronically ill with blood pressure issues… I don’t know if it
has anything to do with that, I just know that they are saying they would like to do some studies
to see if there’s been any kind of a link to that… I see them now and it makes me worry that my
decision to make sure that they were safe was the decision that may not have been…” One
participant reported hearing about reports of potential side effects from the scientific community.
She said, “after my daughter got it [vaccine], all that information came out about the doctor who
developed it, and I think was she from UVA maybe, and there was all these things about how she
was saying she regretted ever developing it and issues it could cause later.” Another mom also
affirmed the fear of side effects especially as it relates to the amount of time the vaccine has been
on the market. This mother reports that she, “held off because… just mixed feelings. Brand new
vaccine, don’t know what side effects were.” The concern about the vaccine’s novelty was a
recurring theme, which participants related to its safety and effectiveness. As one mother stated,
“It is newer… that would be one thing that I would worry about.” In both focus groups,
participants also questioned the vaccine’s long-term effectiveness and worried about sustained
immune response over several decades. As stated by one participant, “I don’t know if it’s been
around long enough to have these longitudinal studies where you see how long does it last… in
other words, does it at some point lose its strength,” and another participant who worried about
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the vaccine’s effectiveness in cancer prevention, “What if it don’t work?...what if it makes it
worse?”
For some mothers, the recommended age range for vaccine initiation created hesitation,
as they did not feel that the vaccine was necessary for their younger children, and thus delayed
vaccine receipt. One participant felt that, “at this point in time that I want them to have it before
they become sexually active… but when I’m dealing with an 11- and 13-year-old… I’ve got a
couple years, and I’m kind of wanting them to have a little more physical maturity.” In both
focus groups, participants discussed perceptions, among their family and social networks, about
the vaccine’s implication for sexual activity: “I did hear from a distant family member, that they
felt like getting that vaccine somehow gave your children permission to be promiscuous.”
However, many of the participants debunked the notion. As one participant illustrated, “that
argument about, that some people do make still, about how you know they are worried that HPV
vaccination in particular will lead to promiscuity which I find bizarre like you [participant] do,
but it’s like what? I mean does getting the MMR vaccination make you go out and actively seek
measles? I don’t think so.”
Some participants also noted additional areas of concern about the HPV vaccine,
specifically, and vaccines in general. One group of mothers stated concern that vaccination could
lead to a sense of false safety and potential delinquency on screening practices. As one
participant stated, “I made sure that my oldest daughter understood that you know once you
became sexually active how important it was to still have your annual exams that just because
you had HPV shot doesn’t mean I don’t ever have to be checked for anything because that is so
far from the truth.” Some participants also discussed aversion to vaccines in general. One mother
said, “Shots make me nervous.” Due to her daughter’s previous adverse reactions from the flu
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shot, one mother who had not vaccinated her daughter stated, “I hesitate injecting another virus
or series of viruses into my child that their body may or may not develop an immunity to.”
Motivations for vaccine acceptance. For mothers who had vaccinated their daughters, the
primary reason for accepting the vaccine was to prevent cancer. Some mothers illustrated this
motivation based on their fear of cancer, “I think I just hear the word cancer and the first thing in
my mind goes whatever we can do to make that not happen for my kid… I’m ready to go.” Some
discussed vaccine acceptance in terms of long-term protection for their daughters and future
generations. One mother felt “…not only is this protecting my daughter, it’s protecting anyone
she comes in contact with…it’s protecting future generations…it’s maybe something that my
grandkids wouldn’t have to worry about if we can continue to get people vaccinated”. One
mother discussed family approval as her reason for vaccinating her daughter in her statement,
“my parents… would have been 100 years old right now… they believed in vaccinations. They
remembered things like when polio was [rampant]...it was like take advantage of these things
that could help prevent disease and conditions whatever you need to do as long as it’s safe.”
Participants also emphasized the theme of cancer prevention, particularly based on
personal or family history of cancer. One mother, who is a cervical cancer survivor, emphasized
her point in reliving her experience and regretted that the vaccine was unavailable for her as a
child, “I wish I had had the shot so then I wouldn’t have to, you know I did have cervical cancer.
So, that’s why I had to have the hysterectomy, and we had one kid, and then we were done. So, if
the shot had been available, I hope that my mom would have said you’re getting it. If it would
have prevented any of that…’cause I don’t want her to get cancer. I don’t want her to have to go
through the same thing that I went through.” Another participant accepted the provider’s
recommendation to vaccinate her daughters because, “both of my grandmothers had cervical
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cancer, and I thought, ‘well, if this is a way to prevent that then that would be a great thing to
do,’ like she [provider] said something… ‘you could protect your children from um…’ So, we
elected to do both of them.”
Additionally, the theme of protection was also discussed in relation to perceived sexual
vulnerability of their daughters. Some participants were motivated to accept the vaccine for their
daughters in the incident of an involuntary sexual encounter. One mother mentioned that, “they
may intend not to be sexually active before they are married, but that’s not to say that they’re not
grabbed by somebody on the street either.” This notion was reaffirmed by another mother who
said a convincing factor for her was the provider’s inference of potential exposure to the HPV
virus even in marriage. According to her, “when the doctor heard that question [necessity of the
vaccine without sexual initiation] his answer was, ‘but you don’t know about the person you
might marry and what they might have done prior to meeting you’…I think that was one of the
two turning points for me.”
In discussing their decisions on whether or not to accept the vaccine, weighing the
perceived risks versus the expected benefits was a recurrent theme among many of the focus
group participants. One mother stated, “you do the risk benefit ratio thing and I could only see
the benefit.” Another mother considered the perceived risk to the benefit of cancer prevention
and reported, “I read through the information, and I know that every vaccine has side effects,
but…if the advantages are going to outweigh the side effects, I thought cancer and side effects….
I’ll go for vaccine.” One mother that felt quite strongly about preventing cancer stated, “if three
shots can prevent it, three… even if I had to hold her down for them to give those shots. And in
all honesty if they had said cut her big toe off on one of her feet if that would mean she would
never get cancer, I would probably do it.”
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Participants who had vaccinated their daughters reported doing so after receiving a
recommendation from their healthcare providers. One mother mentioned hearing about the
vaccine from her physician who “highly recommended it and planned for his own children to
have it, and he said he strongly recommended it be done.” Other mothers reiterated this factor,
buttressing the point that established trust or relationship with the provider made the
recommendation stronger, one mother said, “the other factor was the doctor…has kind of
developed a relationship with my kids, and they trust her so much…If the doctor said it, it is
okay.” Another mother mentioned that these combined factors were of particular importance in
her community, “because we are so small, I think they almost value a [provider’s] personal
opinion as much as they do anything else.” Additionally, one mother stated that notification of
coverage from her insurance company motivated her to accept the vaccine for her daughter.
Finally, participants reported that the vaccine’s inclusion on the regular vaccine schedule
or specifically for their child’s age range was enough reason for them to vaccinate their
daughters. One mother stated that she, “would be okay saying that the government says I have to
give you this, so suck it up,” and another mother said she accepted the vaccine because, “She’s
eligible to have it at this age…Let’s do it.” However, despite their stated motivations to accept
the vaccine, some of the participants reported they rarely approved vaccine receipt immediately
upon recommendation and often delayed their decision. This delayed reaction was reportedly
because of the age range that the vaccine could be received. According to one mother who
eventually received the vaccine for her daughter, “To me that was one thing about the HPV was
that you had this range time that it could be given which I felt like kind of bought you some
time.”
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Perceived Control. When asked whether they felt it was in their control to accept the
vaccine for their daughters, many of the mothers felt that the decision to vaccinate was within
their control. The participants emphasized the role of women and mothers in making general
healthcare decisions for their family, as stated by one of the participants, “it’s usually
women…for themselves and for everybody…” In considering the HPV vaccine specifically,
participants also felt primarily in control as wives, as illustrated, “[my husband] almost would let
me chop the kids’ arms off if I thought that’s what needed to be done,” and as mothers, “I
wouldn’t leave it up to [daughter], she doesn’t want to have a shot…so, that would be completely
in my control.” In addition, some of the participants felt that the vaccine’s status as
‘recommended,’ not ‘required,’ gave them control on whether or not to vaccinate their daughter,
as reflected in this mother’s statement, “The school… requires me to have certain ones, but the
HPV is not one of those, so this particular vaccine is all in my control.”
Perception of daughter’s attitudes. In reflecting on their daughter’s attitudes towards the
vaccine, many participants agreed that their daughters exhibited fear or dislike of shots. One
mother said, “My daughter had such a fear of needles at the time, I kind of gave her a little bit
[of] time.” Another participant reported discussing the vaccine with her daughter who was
fearful of getting the vaccine, “my daughter had started hearing things about it [vaccine] from
her friends who had had it that talked about how much the shot hurt and how some of them had
actually passed out from it, and so that was more of a frightening thing for her.” Participants
also discussed their daughters’ questioning the necessity of the vaccine in the absence of sexual
activity. A participant reported that her daughter asked, “if you’re not having sex, do you need to
get this shot?” One mother mentioned that her daughter made a self-informed decision to receive
the vaccine and considered it standard routine, “when the doctor told us about the vaccine…we
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went home with this long handout, and she read so it wasn’t even coming from us as parents, she
read that and just like well, yeah just like the other vaccines.”
Health communication. In discussing mother-daughter health communication, some
participants reported talking to their daughters about health topics such as hygiene, nutrition, and
personal health conditions. Most participants reported difficulty in talking about sex-related
topics with their daughters. One mother reported that she, “had a hard time with it,” and another
mother felt it was also difficult for the daughters to engage in such conversations with them,
“She don’t want to talk about stuff like that with me, it is a little awkward.” Participants stated a
desire to engage in conversations around sex and reproductive health with their daughters in
order not to repeat history; as discussed by one mother who reported having these conversations
with her daughters in the past, “we just read some things…and somehow that allowed us to talk
about some issues that our parents did not discuss with us… and it was new for us because we
come from a culture where some of the sexual talk is taboo. Nobody, mom didn’t mention
anything like that to me, so we are trying it as parents” Some mothers also indicated a desire for
sex education to be delivered in the schools, “I would be okay if we had… somebody in the
school system, somebody from the health department that would come and talk to them.” In
discussing the HPV vaccine specifically, one of the participants reported that she, “would feel
comfortable talking to my kids about it…About the shot… probably not as much about the
reason….Just you know this could stop you from having cancer or I wouldn’t want to say this
will stop you from having cancer when you start to have sex.”
When asked about their sources of health information, most of the focus group
participants cited their healthcare provider and the internet as their primary source. Some
mothers reported searching sites such as WebMD, and others got their information from social
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media, Facebook specifically. Many of the participants reported their healthcare providers had
talked to them, and in some cases also their daughters, about the vaccine. One mother said, “I
didn’t go in and ask for it. I was just getting my school shots, they brought it up to me.”
However, most of the participants reported that they did not often discuss HPV, the vaccine or
cervical cancer within their social circles. They stated that this was not due to a lack of
willingness to engage in these conversations but, as one mother stated, because, “it doesn’t come
up… I mean if it came up organically you know I would talk.” Another participant also felt that
discussions around cervical cancer and its preventive measure were not often initiated because,
“It’s not one of the sexy cancers.”
Perceptions of community’s acceptance. There was variability in participants’
perceptions of approval of the vaccine within their social networks. While some felt that people
who were close to them would approve of the vaccine, either because they believed in the
necessity of vaccines in general or in the utility of the HPV vaccine in cancer prevention, others
felt that there would be some level of disapproval. These participants felt that the disapproval
would be mostly from older generations who often equated vaccine acceptance with permission
for sexual activity, as one mother cited, “I think in a certain circle they would be supportive…but
older people may not feel that same way. I’ve heard older people say well I don’t know why
these parents are giving them this shot because all that does is like give them permission to go
ahead and get sexually active.”
In discussing their perceptions of vaccine acceptance among residents of Appalachian
Tennessee compared to other communities, participants felt that people in their communities
were more likely to exhibit negative attitudes towards the vaccine primarily based on the implied
sex-related attribute of the vaccine. Participants reported being dissuaded against the vaccine by
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both family members and health professionals. One mother said she “did hear from a distant
family member, that they felt like getting that vaccine somehow gave your children permission to
be promiscuous,” and another cited her experience at point of vaccine receipt, “I took her in uh
to the doctor’s office… and one of the other nursing people said um why are you getting the sex
vaccine?” These statements were reaffirmed by other mothers in the focus groups who had
experienced similar situations. Participants felt that this attitude towards the vaccine was largely
due to the religious conservatism in the area; as one mother illustrated, “I think religion plays a
little bit of a part too. It’s all about your morals. You do not have premarital sex. You know a 16year-old shouldn’t even be doing that. Why would you even consider [vaccine]?” and the sexual
communication climate in the state, both in personal lives and within the school system, as
explained by one of the participants, “…in Tennessee they don’t let you talk about things like
that in school systems, and echoed by another, “It is I don’t talk about it or think about it, it
doesn’t exist…that’s a negative coping skill we see a lot here.”
Perceived barriers in region. While participants did not indicate personal barriers to
receiving the vaccines for their daughters, they felt that barriers existed within the community
that inhibited vaccine acceptance. Some participants felt that affordability of the vaccine could
present significant challenges, because according to one mother, “the biggest barrier is poverty…
The HPV vaccine is very expensive… I think it was over $200 for one, but you consider the
whole series.” Participants also cited accessibility to health facilities and the resultant low
utilization of preventive services as a major barrier, as explained by one participant, “The
emergency room is still the primary care physician for a lot of people that I know,” and echoed
by another, “a lot of people don’t go…for routine stuff.” Additionally, some participants felt that
low education and awareness about the utility of the vaccine and available health services were
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significant barriers to vaccine acceptance. In one of the focus groups, a participant stated, “our
whole community needs education.” Across both focus groups, the phrase ‘knowledge is key
(power),’ was repeated by different participants, as one of them illustrated, “knowledge is key,
because if… if there’s a [free] vaccine somewhere you have to know that you need it…someone
has to tell you that that shot means something for your life.” Lastly, some participants
considered parental consent to receive the vaccine as a significant barrier. One mother stated, “I
wish that they could get it…that they didn’t have to have parental permission to come in and get
the shot.”
Research Aim III. To measure vaccination rates and assess attitudes, perceptions, knowledge and
awareness related to the HPV vaccine among a sample of young women who fall within the
recommended age range (≤26 years) for vaccine dose completion.
About 60% of participants (n = 287) reported they had received at least one dose of the
vaccine, about half (n=160, 56.7%) of whom had completed the 3-dose vaccine series, and 40%
(n=192) reported never initiating vaccine receipt. Of those who had been vaccinated, about onethird (n = 85) reported receiving their first vaccine dose after their first sexual intercourse. Table
4 shows the demographic distribution of respondents. Most participants were between the ages of
18 and 22 years old, 40% identified as Appalachian, and region of residence was almost equally
distributed between rural and sub-urban.
Of the respondents who identified as Appalachian, about 45% (n =217) reported residing
in counties within Appalachian Tennessee (Table 5). Other respondents primarily reside in
counties in either non-Appalachian regions of Tennessee, or other parts of the country.
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Table 4: Demographic Characteristics of Survey Respondents
(N=479)
Characteristics
18-22
23-26

N (%)
457 (95.4)
22 (4.6)

Region of Residence

Rural
Sub-urban
Urban

209 (43.8)
202 (42.3)
66 (13.8)

Appalachian Identity

Yes
No

191 (40%)
287 (60%)

Age

Table 5: Respondents’ Distribution by Appalachian Identity and County of Residence
County of residence
N (%)
Appalachian TN
Other

X2 {p-value}

Appalachian Identity
Yes
No

96 (20.0)
121 (25.3)

95 (19.8)
166 (34.7)

69.96 (p <0.001)

Further analyses investigated associations between hypothesized predictor variables and
vaccination status. The distribution of vaccination status by Appalachian identity and region of
residence did not show statistical significance. Most participants who had been vaccinated
indicated that they had received the vaccine recommendation from their provider and also
reported previous awareness of the HPV virus (Table 6).
On average, participants who had received the vaccine had higher mean scores (M= 8.67;
S.D. = 1.82) on knowledge about HPV’s risks, related diseases, symptoms, modes of
transmissions and preventive measures, compared to those who had not been vaccinated (M=
8.42; S.D=1.78). However, these differences (0.24; 95% C.I. = -14-0.62) were not statistically
significant (t (377) = 1.24, p=0.46).
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Table 6: Descriptive Analysis of Hypothesized Variables and Vaccination Status
Vaccination Status
N (%)
Yes
No

Variables

79 (16.6)
83 (17.4)
30 (6.3)

1.325 (p=0.516)

Appalachian Identity

Yes 119 (24.9) 72 (15.3)
No 168 (35.2) 119 (24.9)

0.678(p=0.410)

HPV Awareness

Yes 244 (51.0) 134 (28.0)
No
42 (8.8) 58 (12.1)

16.732(p<0.001)

Provider recommendation

Yes 193 (55.5)
No
32 (9.2)

Region of residence

Rural 130 (27.3)
Urban 119 (24.9)
Sub-urban
36 (7.5)

X2 {p-value}

63 (18.1) 48.836 (p<0.001)
60 (17.2)

Overall, the distribution of median scores for participants’ perceptions of equality in
gender roles (U=31.578; z=2.72; p<0.05) and normative beliefs (U = 11,528; z = -10.78; p =
<0.001) differed by vaccination status (Table 7). Participants who had been vaccinated also had
higher positive perceptions of gender roles (Mdn = 1.57; IQR = 0.86) and higher agreement
(Mdn = 4.00; IQR = 2.00) that the vaccine was acceptable within their interpersonal network
compared to those who had not initiated vaccination (Mdn=1.86; IQR = 1.29; Mdn = 3.00; IQR
= 0.67, respectively). Additionally, perception of maternal endorsement of the vaccine differed
significantly among those who had been vaccinated compared to those who had not been
vaccinated (U = 9, 610; z = -11.94; p = <0.001). Students who had not initiated vaccine uptake
had higher disagreement (Mdn = 3; IQR = 1.00) that their mother approved of the vaccine
compared to those who report vaccine uptake (Mdn = 4; IQR = 2).
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Table 7: Mann-Whitney U Test Comparing Participants’ Perceived Norms
Variables

Vaccination Status
Yes
No
Median(IQR) Median (IQR)

Test Statistics

Perception of equality
gender roles

1.57(0.86)

1.86(1.29)

U=3,578; z=2.72; p<0.05

Perceived norms

4.00(2.00)

3.00(0.67)

U=11,528; z= -10.78; p<0.001

Perception of
maternal
endorsement

4.00(2.00)

3.00(1.00)

U=9,601; z= -11.94; p<0.001

Comparing participants’ perceptions towards both the vaccine and the virus, there was a
weak statistical difference (p=0.05) in perceived susceptibility to HPV infection by vaccination
status (Table 8). However, participants who had received the vaccine had higher agreement that
the vaccine would be effective in preventing HPV, and indicated less concern about potential
side effects from the vaccine. Also, while the agreement rates for perceived control in decision to
receive the vaccine did not show statistical difference across each category, students who had
received the vaccine had higher perceived ease of vaccine receipt (Mdn=2.00; IQR =1.00)
compared to those who had not received the vaccine (Mdn=3.00; IQR=1.00).
Final logistic regression models analyzed relationships between significant predictor
variables and vaccination status (Table 9). The results of the analyses indicated that the model
was a good fit with an overall predictive accuracy of 83%. Univariate analysis of the predictor
variables showed that positive perceptions of gender roles, perceived norms, maternal
endorsement, provider recommendation, and perceived vaccine effectiveness, potential side
effects, and ease of getting the vaccine were all associated with vaccine acceptance, while
Appalachian identity did not show significant association.
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Table 8: Mann-Whitney U Test Comparing Participants’ Perception Towards HPV and The Vaccine
Vaccination Status
Yes
No
Median(IQR) Median (IQR)

Variables

Test Statistics

I can get HPV

3.00(1.00)

3.00(1.00) U=29,298; z=1.95; p=0.05

The vaccine cannot really prevent
HPV

2.00(1.00)

3.00(1.00) U=32,817; z=4.64; p<0.001

I am worried about side effects from
the vaccine

2.00(2.00)

3.00(2.00) U=37,041; z=7.68; p<0.001

For me to receive the HPV vaccine is
easy

3.00(1.00)

2.00(1.00) U=36,660; z=7.42; p<0.001

The decision to receive the vaccine is
beyond my control

2.00(2.00)

2.00(2.00)

U=25,624; z= -0.60; p=0.546

Whether I get vaccinated or not is not
up to me

3.00(2.00)

3.00(2.00)

U= 25,911; z= -0.32; p=0.75

After controlling for confounding, multivariate analysis showed that maternal
endorsement, provider recommendation, and concern about potential side effects from the
vaccine were strongly associated with vaccine acceptance. Perception of normative approval also
showed moderate association (p=0.05) with vaccine acceptance.
Provider recommendation was the greatest predictor of vaccine acceptance. Compared to
those who had not been vaccinated, participants who had been vaccinated were more than four
times (OR=4.59; CI=2.36-8.93; p<0.001) as likely to have received a provider’s recommendation
for the vaccine. Participants who had received the vaccine were almost twice as likely (OR=1.95;
CI= 1.32-2.88; p=0.001) to agree that their mother approved of vaccine receipt compared with
those who had not been vaccinated. Participants who had been vaccinated were also less likely to
indicate concern about potential side effects from the vaccine. Finally, those who had been
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vaccinated were 57% (OR= 1.57; CI= 1.00-2.47; p= 0.05) more likely to perceive that people
within their social circles would approve of their vaccine receipt compared to those who had not
been vaccinated.
Table 9: Univariate and Multiple logistic regression analyses showing association between hypothesized predictor
variables and vaccination status
Predictor Variable

Crude
OR

95% C.I

P-value

Adjusted
OR

95% C.I

P-value

Perceptions of gender roles

0.68

0.53-0.87

<0.05

1.00

0.63-1.58

0.99

Perceived norms

3.33

2.63-4.22

<0.001

1.57

1.00-2.47

0.05

Maternal endorsement

3.41

2.60-4.46

<0.001

1.95

1.32-2.88

0.001

5.74
-

3.43-9.61
-

<0.001
-

4.59
-

2.36-8.93
-

<0.001
-

2.70
2.01
0.76
0.99
-

0.78-9.34
0.64-6.25
0.25-2.34
0.28-3.42
-

<0.001
0.12
0.23
0.63
0.98
-

0.52
0.96
0.97
0.80
-

0.06-4.62
0.13-6.98
0.13-7.16
0.10-6.22
-

0.87
0.56
0.97
0.98
0.83
-

11.64
5.46
2.75
1.46
-

4.83-28.83
2.25-13.26
1.19-6.36
0.58-3.65
-

<0.001
<0.001
<0.001
<0.05
0.42
-

2.34
2.76
2.46
0.69
-

0.60-9.07
0.73-10.36
0.68-8.84
0.18-2.63
-

<0.05
0.22
0.13
0.17
0.58
-

6.33
2.22
0.69
1.72
-

1.87-21.44
0.68-7.28
0.21-2.32
0.44-6.72
-

<0.001
<0.01
0.19
0.55
0.43
-

1.40
0.55
0.47
1.12
-

0.17-11.04
0.07-4.28
0.06-3.90
0.12-10.74
-

0.14
0.75
0.57
0.48
0.92
-

Provider recommendation
Yes
No
The vaccine cannot really prevent
HPV
Strongly disagree
Moderately disagree
Neutral
Moderately agree
Strongly agree
I am worried about side effects from
the vaccine
Strongly disagree
Moderately disagree
Neutral
Moderately agree
Strongly agree
For me to get the vaccine is
easy
Strongly disagree
Moderately disagree
Neutral
Moderately agree
Strongly agree

Stratified regression analyses of the significant variables by Appalachian identity
revealed some differences (Table 10). Predictive associations among respondents who did not
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identify as Appalachian showed similar patterns with the larger sample; perception of maternal
endorsement, receiving a provider’s recommendation, perception that the vaccine is acceptable
within their social circles, and concern about vaccine side effects were significantly associated
with vaccine acceptance. However, among respondents who identified as Appalachian,
perception that their mothers’ approved of the vaccine and receiving a provider’s
recommendation were almost equally associated with vaccine acceptance.
Table 10: Univariate and Multiple logistic regression analyses showing association between hypothesized predictor
variables and vaccination status grouped by Appalachian Identity
Appalachian
Identity
(No) N=197
Adjusted
95% C.I
OR

Predictor Variable

P-value

Appalachian
Identity
(Yes) N=144
Adjusted
95% C.I.
OR

P-value

Perceived norms

1.84

1.03-3.26

0.04

1.26

0.61-2.62

0.53

Maternal endorsement

1.79

1.09-2.94

0.02

2.47

1.28-4.76

<0.01

Yes
No

4.77
-

2.07-10.98
-

<0.001
-

4.10
-

1.45-11.60
-

<0.01
-

I am worried about side effects
from the vaccine
Strongly disagree
Moderately disagree
Neutral
Moderately agree
Strongly agree

3.28
1.59
1.16
0.42
-

0.53-20.11
0.27-9.19
0.21-6.32
0.07-2.59
-

0.05
0.20
0.61
0.87
0.35
-

1.78
4.84
3.93
1.42
-

0.26-12.00
0.66-35.76
0.67-23.11
0.20-10.28
-

0.29
0.55
0.12
0.13
0.73
-

Provider recommendation

Among respondents who identified as Appalachian, perception of maternal endorsement
of the vaccine showed stronger predictive association (OR = 2.47, P <0.01) with vaccine
acceptance compared to respondents who did not identify as Appalachian (OR = 1.79, P<0.05).

75

Research Aim IV. To explore associations between mother-daughter sexual health
communication and vaccine uptake in Appalachian Tennessee.
The survey assessed maternal communication in three categories: content of motherdaughter communication, participants’ reception and satisfaction with mother-daughter
communication, and overall mother-daughter relationship.
Most participants reported discussing at least one of the eleven topics with their mothers.
There was a statistically significant difference in the distribution of mother-daughter sexual
health communication by vaccination status. Participants who had been vaccinated reported
talking to their mother about birth control, safe sex practices, sexual intercourse, HPV
vaccination, and cervical cancer screening, more often than those who had not been vaccinated
(Table 11).
Table 11: Mother-Daughter Communication and Vaccination Status

“My mother talked to me about…”

Vaccination Status
N (%)
Yes
No

X2 {p-value}

Birth control

Yes 229 (48.9) 134 (28.6)
No 53 (11.3) 52 (11.1)

5.40 (p<0.05)

Safe sex practices

Yes 210 (44.9) 114 (24.4)
No 72 (15.4) 72 (15.4)

9.14(p<0.05)

Sexual intercourse

Yes 213 (45.6) 123 (26.3)
No 68 (14.6) 63 (13.5)

5.19(P<0.05)

HPV vaccination

Yes 205 (44.0) 75 (16.1) 48.87 (p<0.001)
No 76 (16.3) 110 (23.6)

Cervical cancer screening

Yes
No

178(38.3)
85 (18.3) 14.89 (p<0.001)
102 (21.9) 100 (21.5)

Reception of mother-daughter sexual health communication differed significantly among
those who had been vaccinated compared to those who had not been vaccinated (U =22,468; z =
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-2.63; p = <0.05). Those who reported not receiving the vaccine were less receptive (Mdn =
3.18; IQR = 1.80) when their mothers talked to them about a range of sexual and reproductive
health topics compared to those who reported vaccine receipt (Mdn = 3.55; IQR = 1.91).
Participants who had been vaccinated reported higher satisfaction (U =23,093; z = -2.24; p =
<0.05) with the overall communication with their mothers (mean rank = 244.82; Mdn= 4.00,
IQR = 2.00) compared to those who had not been vaccinated (mean rank 217; Mdn= 4.00, IQR =
2.00).
Additionally, as illustrated in Table 12 above, participants’ overall relationship
satisfaction with their mothers differed significantly among those who had been vaccinated
compared to those who had not been vaccinated (U =22,184; z = -2.77; p = <0.006).
Table 12: Mann-Whitney U Test Comparing Participants’ Mother-Daughter Communication
Vaccination Status
Yes
No
Median(IQR) Median(IQR)

Variables

Test Statistics

Reception of communication

3.55(1.91)

3.18(1.80)

U =22,468; z = -2.63; p = <0.05

Satisfaction with communication

4.00(2.00)

4.00(2.00)

U =23,093; z = -2.24; p = <0.05

Satisfaction with relationship

4.13(1.43)

4.00(1.67)

U =22,184; z = -2.77; p = <0.05

Those who reported vaccine acceptance (Mean rank = 248.05; Mdn = 4.13; IQR = 1.43)
perceived their relationships with their mothers more positively compared to those who had not
been vaccinated (Mean rank = 212.77 Mdn = 4.00; IQR = 1.67). Specifically, there was no
significant difference in the distribution of participants’ perception of their mother’s availability
to talk with them, however participants differed in their perceptions that their mothers
empathized with specific situations they discussed (U =22,521; z = -3.312; p = 0.001). Those
who reported vaccine acceptance indicated higher agreement that their mothers empathically
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conversed with them (mean rank = 209.20; Mdn = 4.00; IQR = 1.33) compared to participants
who had not been vaccinated (mean rank = 250.41; Mdn = 4.00; IQR = 1.67).
Triangulation of Findings
Analysis of findings from the interviews with healthcare providers and focus groups with
mothers revealed several crosscutting themes (Table 13). Participants in both groups considered:
affordability of the vaccine, aversion to pain (fear of needles), the lack of school-entry
requirement for the vaccine, concern about vaccine safety, novelty of the vaccine, perceived
implication of sexual activity, necessity of the vaccine for adolescents, and low
education/awareness about HPV and the vaccine, as potential barriers to vaccine acceptance.
Participants further inferred that these barriers were in part due to the influence of religious
values and culture around sexual health within the community. Interestingly, the theme that
receipt of the vaccine could lead to a decline in cervical cancer screening rates emerged as a
concern across both groups. Convergent themes on facilitators of vaccine acceptance revealed
that: emphasizing benefits for cancer prevention, receiving a strong and personal provider
recommendation, intention to protect women in the event of involuntary sexual encounters, and
including the vaccine on the schedule of required vaccines, were likely to increase vaccination
rates.
Table 13: Convergent Themes from the Interviews and Focus Groups
Themes

Provider quotes

Mother quotes

Cost is an issue especially when it was
new because you know if we were
talking about getting the vaccine, a
really early question would be does my
insurance cover it?”

The HPV vaccine is very expensive…
I think it was over 200 for one, but
you consider the whole series.”

Barriers to vaccine acceptance
Affordability
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Table 13 continued: Convergent Themes from the Interviews and Focus Groups
Pain averse

Vaccine requirement

Concern about vaccine safety

Novelty of the vaccine

Implied sexual activity

Age
appropriateness/necessity

Low education/awareness

Community context
Religious conservatism

…There’s just the general fear of
needles…nobody, even when I have
kids that are old enough to make their
own decisions, often they don’t wanna
do it.”

My daughter had started hearing
things about it [vaccine] from her
friends who had had it that talked
about how much the shot hurt and
how some of them had actually
passed out from it and so that was
more of a frightening thing for her.”
…The HPV of course right now kind of The school… requires me to have
falls through the cracks. It’s not
certain ones, but the HPV is not one
required, it’s recommended.”
of those so this particular vaccine is
all in my control.
I have a friend who has two teenage or Held off because… just mixed
pre-teens and I asked are you going to feelings. Brand new vaccine, don’t
get it? And she said no, there are too
know what side effects were
many side effects.”
a lot of parents feel like this is a new
It is newer… that would be one thing
vaccine, even though the vaccine’s
that I would worry about
being around for several years, they
feel like it’s still new, and therefore
may not be safe.
They think it’s um an okay to have sex Did hear from a distant family
um if they get it for their children.”
member, that they felt like getting that
vaccine somehow gave your children
permission to be promiscuous
The specific resistance to the idea that At this point in time that I want them
to have it before they become sexually
my children is going to be sexually
active… but when I’m dealing with an
active or can be exposed to this, uh
11 and 13-year-old… I’ve got a
parents really don’t want to think
couple years and I’m kind of wanting
about that when they’ve got an eleven- them to have a little more physical
year-old
maturity.
The specific resistance to the idea that Knowledge is key because if… if
my children is going to be sexually
there’s a [free] vaccine somewhere
active or can be exposed to this, uh
you have to know that you need
parents really don’t want to think
it…someone has to tell you that that
about that when they’ve got an eleven- shot means something for your life
year-old
So I think that we’re in the Bible belt
and according to the Bible we should
wait or according to religious…
ideology we should wait until we’re
married to have sex and so the thought
process is well my kid is not going to
have sex before they are married so
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I think religion plays a little bit of a
part too. It’s all about your morals.
You do not have premarital sex. You
know a 16-year-old shouldn’t even be
doing that. Why would you even
consider [vaccine]?

Table 13 continued: Convergent Themes from the Interviews and Focus Groups

Abstinence-only sex
education

why would they need that vaccine
anyway?
I think here there’s probably a higher
concentration of people who are really
focused on kind of abstinence only
education for their kids

Concern about the vaccine
Impact on PAP tests

The only concern I think I would have
is that it could potentially make people
think they don’t need PAPs and once
you know, I think it would be easy for
people to make that connection like
well this is supposed to protect me
against the thing that PAP smears test
me for so now I don’t need PAPs
Facilitators of vaccine acceptance
Emphasize benefits for
I think if they would have marketed it
cancer prevention
from day one as a cancer vaccine
instead of even using the word sex that
they would have a different
Strong and personal provider One of the things that makes a
difference in people getting a vaccine
recommendation
is providers giving a strong
recommendation
and patients are more likely to get it if
you give them kind of a confident
recommendation as their provider

Explain sexual vulnerability
of women

I tell parents that y’know, your
daughter can be lawfully wed to one
man and have sex with that person
only and still if he brings the virus into
the marriage she’s the one that pays
the price

Vaccine requirement

If it were required we’d give it more
easily, and I have a feeling if it were
required some parents wouldn’t even
ask what it was who might otherwise
deny it
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In Tennessee they don’t let you talk
about things like that in school
systems

I made sure that my oldest daughter
understood that you know once you
became sexually active how important
it was to still have your annual exams
that just because you had HPV shot
doesn’t mean I don’t ever have to be
checked for anything because that is
so far from the truth
This is a vaccine that could possibly
prevent my child from having cancer
in the future. Why would I not come
in here and get this vaccine?”
Highly recommended it and planned
for his own children to have it and he
said he strongly recommended it be
done
Because we are so small, I think they
almost value a [provider’s] personal
opinion as much as they do anything
else.”
When the doctor heard that question
[necessity of the vaccine without
sexual initiation] his answer was but
you don’t know about the person you
might marry and what they might
have done prior to meeting you…I
think that was one of the two turning
points for me.”
Would be okay saying that the
government says I have to give you
this so suck it up,

These findings provide exploratory validation of the study’s hypothesized model (figure
5). The constructs assessed in the integrated behavioral model suggest that individuals who
exhibit positive attitudes and low negative perceptions towards the vaccine were more likely to
accept it, either as a patient or provider. Additionally, knowledge and awareness about the virus
and the vaccine, and the perceived utility of the vaccine in cancer prevention also directly
influenced vaccine acceptance. While perceptions of control did not appear to have any influence
on vaccine acceptance, perception of existing barriers to affordability of the vaccine and
accessibility to health services were predictive of low vaccine acceptance.

Figure 5: Hypothesized Model of HPV Vaccine Acceptance in Appalachian Tennessee

Exploring vaccine acceptance from a systems perspective reveals convergent barriers and
facilitators of vaccine acceptance, across the family context and healthcare sector. In addition,
the perception of sex-related topics (e.g., sexual health, sex education, etc.) within Appalachian
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Tennessee appears to have subliminal influence on HPV vaccine acceptance among residents of
the community (Figure 6).
Summary of Study Findings
Basis for vaccine resistance
Novelty of the vaccine was the most prevalent theme among providers and mothers.
Participants’ concerns about long-term side effects were often discussed in relation to the period
that the vaccine has been existence. Providers often cited parents’ resistance to the vaccine based
on its relatively recent development. Mothers in the study reaffirmed this belief and drew
parallels between the novelty of the vaccine and perceived side effects. They indicated that their
concerns about the vaccine’s potential side effects and its impact on health and health behaviors
were largely due to the novelty of the vaccine and the limited data on longitudinal research.

Community Culture

Climate on sex –
related topics
Mother-daughter
communication







Healthcare
System

Family
Context

Resistance
Inadequate information
Potential side effects
Novelty of the vaccine
Affordability
Vaccine requirement

Health
education/awareness





Acceptance
Benefits for cancer prevention
Strong and personal provider
recommendation
Sexual vulnerability of women

Figure 6: Depicting the Triangulated Findings Using the Multi-Sectorial Model of Systems Thinking
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Providers also discussed perceived parental beliefs that the vaccine would encourage
sexual initiation and risky sexual behavior; however, mothers in the study denied this belief and
instead reported familial and interpersonal perceptions about the vaccine’s implication for sexual
activity. Also, while none of the mothers reported that they specifically resisted the vaccine
because of implied permission for sexual activity, they often indirectly relayed this perception as
they discussed refusing or delaying the vaccine based on relevance of the vaccine given their
daughter’s sexual naiveté. This perception was not limited to parents alone, as some mothers
reported that their daughters also questioned the vaccine’s necessity because they were not
sexually active. To counter this concern, participants in the study report giving (healthcare
providers) and receiving (mothers) rebuttals stressing the notion that women are vulnerable to
involuntary exposure from unfaithful partners or sexual assault.
Other recurrent themes from the interviews and focus groups indicated that affordability
of the vaccine, vaccine safety, the lack of school-entry requirements for the vaccine, and its
implication for adolescents’ sexual activity were predominant barriers to vaccine acceptance.
Results from previous studies indicate that inability to afford the vaccine could inhibit patients,
especially those of low SES populations, from receiving the vaccine (Holman et al., 2014). The
findings from this study add additional context to this barrier, as participants perceived the high
price of the vaccine and emphasized the extent of insurance coverage as a significant determinant
of vaccine acceptance. While providers acknowledged this barrier, they were also aware of
available resources, within the health department, which could make the vaccine available to
uninsured or underinsured patients. However, many parents were unaware of these resources,
thus highlighting the gap in availability, accessibility and utilization of health care services.
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Congruent with existing reports, individuals who indicated concern about potential side
effects from the vaccine were also more likely to resist the vaccine (Hutson et al., 2011a). Across
the triad, providers, mothers and young adult women revealed concern about vaccine safety as a
barrier to vaccine acceptance. Interestingly, mothers and providers focused on the short-term side
effects (pain, fear of needles, adverse reaction) as reasons why parents and adolescents in
particular, may resist the vaccine. Only a few participants described specific long-term side
effects, and others referred to it as an ‘unknown’ that may occur in the future. Not surprisingly,
fear that the vaccine may be detrimental to their child’s health would deter many parents from
accepting the vaccine. However, many providers perceived that the existing concern about longterm side effects was due to misinformation, largely propagated by the internet. The status of the
vaccine as recommended and not required for school entry appeared to be a barrier, especially
from the provider perspective. Providers perceived that if the vaccine were required, there would
be less resistance to it, and parents would be less likely to question its effectiveness, safety, and
necessity. Mothers also reaffirmed this notion based on the idea that if the vaccine was not
required then it wasn't as pertinent.
Finally, in discussing the community’s attitudes towards the vaccine, participants focused
on the existence of predominant perceptions about the vaccine's implication on sexual activity.
The association of abstinence-only education, both within the school system and community
context, and religious values in the region were cited as the foundation for the community
resistance. This theme is evident in the contrasting response between the HPV vaccine and other
recommended vaccines. As participants noted the similar protective factors of the HPV vaccine
and other readily accepted vaccines, and the difference in community acceptance, and inferred
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that the perception of implied sexual activity with the vaccine was due to the underlying theme,
which deterred acceptance of the HPV vaccine.
Vaccine Acceptance
Receiving a provider’s recommendation to get the vaccine emerged as a predominant
facilitator of vaccine acceptance across the triad. Providers acknowledged their role and
indicated that patients were more likely to receive the vaccine if they recommended it during
routine vaccination visits. Mothers reaffirmed this idea, and results from the multivariate analysis
indicated that receiving a provider’s recommendation was the most significant predictor of
vaccine acceptance among young women. While existing studies have illustrated this
association, participants in this study particularly highlighted the importance of these
recommendations being ‘strong and personal.’ Participants indicated that recommendations that
portrayed the vaccine as a necessity instead of a suggestion, and cited either the provider or a
relatable case as an example, had more success in vaccine acceptance. Both providers and
mothers noted that among this population, the recommendation was often more effective when
received from a trusted healthcare professional with whom a personal relationship has been
established. However, as noted by the participants, due to limited accessibility, few residents
utilized primary care regularly, thus established provider relationships might not be the norm in
the region.
The context in which the recommendation is framed also emerged as a significant factor
in vaccine acceptance. Parents and providers reported that the recommendation was often more
effective when framed using personal examples, and even more effective when the vaccine’s
utility in cancer prevention was at the forefront of the recommendation. Many of the mothers
discussed weighing the perceived risks and benefits, cancer prevention being the most significant
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benefit against which many of the risks were perceived to be minimal. Indeed, parents who had a
personal or family history of cancer showed stronger feeling towards the vaccine's utility in
cancer prevention.
Mother-Daughter Communication
While many mothers acknowledged the need to engage in sexual health conversations
with their daughters, they also perceived difficulty in having these discussions, and instead
indicated a preference for sexual health education in schools. Assessment of mother-daughter
communication among college-aged women revealed important differences. Compared to those
who had not been vaccinated, respondents who had been vaccinated often discussed sexual
health and behavior with their mothers and also reported greater satisfaction in their overall
communication and relationship with their mothers. While these factors were not significant
predictors of vaccine acceptance, they highlight the link between maternal sexual health
communication and positive health.
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CHAPTER 5
DISCUSSION
Recommendations for Improving Vaccine Acceptance in Appalachian Tennessee
Cervical cancer is a preventable health burden that disparately affects women in rural
Appalachia. The HPV vaccine remains the key primary prevention tool to address this health
disparity, however, vaccine acceptance rates are lower than expected, particularly among highrisk populations such as residents of Appalachian Tennessee. Previous studies highlight potential
barriers to vaccine acceptance; however, many of these studies were conducted in nonAppalachian regions. Considering the ‘distinctiveness’ of each Appalachian sub-region, it is
important to recognize the factors that influence vaccine acceptance specific to each region in
order to increase vaccination rates. This study, as an exploratory step to investigate HPV vaccine
acceptance among key stakeholders – healthcare providers, mothers with adolescent daughters,
and young adult women in Appalachian Tennessee – reveals several convergent themes among
the triad. These themes particularly highlight the discrepancy in health communication and
vaccine policy as leverage points for action (Figure 7).
The existence of negative perceptions about the vaccine’s attributes is largely fueled by
the propagation of inaccurate and inadequate health information. Parental concern about the
vaccine’s side effects can be attributed to the prevalence of anti-vaccine messages and the sparse
availability of accurate scientific information. Therefore, if HPV vaccination rates are to be
increased, health communication messages must proactively counter the propagation of false
information by debunking the myths and misconceptions about HPV vaccine safety and make
this information easily available to the public. This emphasis on communication is further
illustrated within the healthcare sector, as the receipt of a provider’s recommendation is a key
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predictor of vaccine acceptance. The context in which the recommendation is framed also
emerged as a significant factor in vaccine acceptance. Parents and providers reported that the
recommendation was often more effective when framed using personal examples, and even more
effective when the vaccine’s utility in cancer prevention was at the forefront of the
recommendation.
Barriers

The vaccine
recommendation
was not relevant for
me/my daughter.

The vaccine is too
expensive/my
insurance does not
cover it.

The vaccine is
new. It may have
unknown side
effects.

Community awareness

Policy changes

Strategy
Patient-provider
communication




Encourage providers to
utilize confident and
exemplary
recommendations
Emphasize the benefits
of the vaccine in cancer
prevention





Raise awareness about
available health
resources
Actively disseminate
accurate information
about the vaccine’s
attributes and
importance





Update vaccine
schedule to require the
HPV vaccine for
school-entry
Mandate insurance
coverage in accordance
with policies for
preventive services

Figure 7: Barriers to HPV Vaccine Acceptance and Potential Strategies for Communication and Policy
Change
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Facilitation of HPV vaccine acceptance in Appalachian Tennessee would largely benefit
from provider messages that emphasize the main objective of the vaccine in preventing cervical
cancer. By accurately addressing the issues that are of importance to parents, providers can
effectively frame their message to focus on the most significant perceived benefits of vaccine
acceptance. Effective health communication messages can also address vaccine resistance based
on the perceived implication of vaccine receipt on adolescents’ sexual activity. Provider
messages that asked parents to consider their daughter’s sexual vulnerability appeared to be
effective in addressing resistance based on perception of implied sexual activity and should be
included in the healthcare provider toolkit to frame recommendations for the HPV vaccine.
The importance of provider-patient communication is additionally evident in the gap
between provider awareness about available health resources and lack of patient/community
awareness. Therefore, to address vaccine affordability as a barrier, health promotion strategies
should encourage communication between providers and patients which ensure that information
on health resources are not retained in silos within the healthcare system but are adequately
propagated within the community. Health communication messages that raise awareness of
available resources within each community and increase ease of accessibility to these resources,
so that residents are aware of the need, availability and subsequent provision of the vaccine,
would be effective in increasing vaccine acceptance.
These communication messages will also have far-reaching effects if implemented with
supportive health policies, particularly policy updates that require the HPV vaccine for schoolentry. Including the HPV vaccine along with other mandated vaccines, such as TDaP (Tetanus,
Diptheria and Pertussis), Meningitis, and Hepatitis B, may be an effective way to increase
acceptance. These policy changes should be driven by benevolent motivations for vaccine
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recommendation, in that cervical cancer is a severe disease which can be prevented, and nonmaleficence in regards to the absence of any documented adverse effects from the vaccine which
render it unsafe. In comparing HPV infections to similar vaccine-preventable diseases, Hepatitis
B is an STI from which we have observed a decrease in incidence rates due to mandated
vaccinations (Field & Caplan, 2008). Vaccine requirement adds weight to a provider’s
recommendation, as parents are more likely to make inference of the necessity and importance of
the vaccine if it is required by health care professionals. Updating the vaccine administration
schedule would also ensure insurance coverage, as the vaccine would be categorized as a
preventive service, and would thus address the concern of cost and affordability.
Study Limitations
The study findings should be interpreted within the context of existing limitations.
Participation Bias
Many of the providers practiced within an academic or health department clinic and
agreed to participate on an entirely voluntary basis. Therefore, there is the possibility that those
who agreed to participate in the study already had positive attitudes towards the vaccines, and
those who declined participation had negative perceptions. This phenomenon could have led to a
participation bias in the findings. This study was originally designed to account for this bias
through purposeful recruitment of participants from diverse communities. However, recruitment
was challenging, and most providers practiced in a single county. Additionally, focus group
participants were predominantly of higher education and income level and do not adequately
represent the majority of women in Appalachian Tennessee. Moving forward, this bias can be
addressed by recruiting a larger and more diverse sample of participants.
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Self-reporting Bias
Assessment of vaccine acceptance among the patient population and recommendation
among providers was based on self-report, which holds the potential for misrepresentation.
Future studies can assess vaccine acceptance by using clinic records to confirm individual
reports.
Social Desirability Response
Given the methodology of qualitative research (i.e., face-to-face interviews with
healthcare providers), there is the potential that participants provided responses which they
deemed socially and professionally acceptable. Also, because of the nature of focus group
participation, participants may have felt constricted in openly discussing their opinions and
beliefs for fear of judgment. However, given that some of the questions were not sensitive in
nature, this bias is expected to have limited effects on the study findings.
Investigator Effect
The investigator’s demographic characteristic as an outsider may have influenced the
dynamics of the interviews and focus groups, especially considering the region’s preference for
close-knit interactions. However, this data collection protocol was intrinsic to the scope and
purpose of the study.
External Validation
Due to limited resources, data analysis was only conducted by the PI as such coding
strategies could not be validated by an additional researcher. Given adequate resources, the study
protocol would have included a research assistant to analyze the qualitative data, thus ensuring
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the validity of findings. However, the study design incorporated triangulation from different
methods to confirm findings from each independent phase in order to increase validation.
Inadequate Survey Items
Finally, although the overarching objective of the study was to explore sociocultural
factors of vaccine acceptance in Appalachian Tennessee, the survey measures were not designed
to assess these constructs. Future studies can employ validated survey measures that assess
cultural identity and associated indices with vaccine acceptance.
Directions for Future Research
This exploratory study is a first step in understanding vaccine acceptance in Appalachian
Tennessee. Future studies can build on this work to address the limitations and identify specific
predictors of vaccine acceptance among this priority population.
Study 1: Developing an Empirically-Evaluated Instrument to Assess Sociocultural Predictors of
HPV Vaccine Acceptable among Appalachian Women
The inadequacy of the survey to assess sociocultural predictors was a major limitation of
this study. This was due to the lack of existing instruments to comprehensively assess
sociocultural predictors of HPV vaccine acceptable among Appalachian women. Considering the
specific perceptions towards the HPV vaccine relative to other vaccines and the unique cultural
identity of Appalachian regions, it is important to investigate the predictors of HPV vaccine
acceptance specific to the region. Future studies should utilize information from focus groups to
develop theory-based items and scales that assess attitudes, perceptions, normative beliefs,
indices of Appalachian identity, and cultural norms. The survey could then be refined using
qualitative and quantitative content review and cognitive interviews to ensure reliability and
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validity of each measure. The final items and scales would then be pilot-tested among mothers
who have daughters within the eligible age range for vaccine receipt.
Study 2: Investigating Unvaccinated Young Women
This study explored self-reported vaccination status and associated attitudes and
perceptions among college-aged women; however, it did not fully explore correlates of nonvaccine acceptance. For a subsequent study, it would be useful to understand why young women
who are otherwise eligible have not been vaccinated. This prospective study can utilize a mixed
methods strategy where participants complete the survey developed in Study 1 above and also
indicate their vaccination status. Those who report non-vaccination would then be invited to
participate in interviews. Ideally, the sampling frame for this study should include a more diverse
population of young women across Appalachian Tennessee to ensure a more representative
sample.
Study 3: HPV Vaccine Practice and Acceptance among the Triad in a Clinic Setting
The limitation induced by self-reporting of vaccine acceptance was another
methodological flaw of this study. To address this bias, another study can utilize a strategy
conducted in a clinic setting where providers, mothers and adolescents can be recruited to share
their perceptions, beliefs and practices. Using clinic rosters to identify prospective participants,
each triad would be approached after a visit where adolescents were eligible to be vaccinated.
The study would be introduced and consenting participants would be immediately surveyed
using the measurement instrument developed in Study 1 above. Vaccination status would then be
validated using patients’ records. This study would assess correlates of provider recommendation
(i.e., frequency of recommendation, provider attitudes, etc.), and patients’ (parent and
adolescent) attitudes, perceptions and willingness to accept the vaccine.
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Contributions to Public Health
The findings from this study provide foundational insights about HPV vaccine
acceptance in Appalachian Tennessee. These findings provide the foundation on which
subsequent studies can conduct broader investigations to identify determinants and deterrents of
the vaccine in the region. By identifying and understanding factors that are considered beneficial
or controversial in the region, health promotion interventions designed to increase awareness and
effectively relay the benefits of the HPV vaccine can be tailored to address the specific needs of
the community. These strategies would increase vaccination rates and address the cervical cancer
disparity among rural Appalachian women
Conclusion
While the HPV vaccine may be gaining acceptance, vaccination rates are still low,
largely due to misconceptions about the vaccine’s side effects and effectiveness. Major barriers
to vaccine acceptance include: cost and age of the vaccine, vaccine safety, the vaccine’s
requirement status, and its implication for adolescents’ sexual activity. Most of these perceptions
are driven by the underlying climate on sex-related topics within the larger community. On the
other hand, vaccine acceptance in the region is fostered by perceived benefits in cancer
prevention and receipt of strong and personal provider recommendations.
Public health efforts to increase vaccination rates should increase awareness about the
need for the vaccine and availability of resources. Health education and provider messages
should focus on the vaccine’s utility in cancer prevention. Future studies should employ
validated models and measures to identify the specific predictors of HPV vaccine acceptance in
Appalachian Tennessee. Identifying and understanding these factors specific to the region will
illustrate the different perspectives of a ‘culturally-distinctive’ population and highlight the
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leverage points for action. These studies will inform the development of future interventions
which are crucial to improving HPV vaccination rates, and essential to maximizing the primary
benefit of the vaccine in addressing the existing cervical cancer disparity in the region.
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APPENDICES
Appendix A
Interview Invitation Letter
Hello,
My name is Tosin Ariyo, and I am a doctoral student in Community and Behavioral
Health at East Tennessee State University (ETSU). I am conducting a study that
involves exploring factors that influence the decisions to accept the Human Papilloma
Virus (HPV) vaccine for adolescent girls in Northeast Tennessee.
I am looking for clinicians who practice in the Northeast Tennessee region and
administer vaccines as part of their clinical practice to join this study which involves
participating in an interview and completing a short survey. The interview will last about
30 minutes and will take place at a location of your convenience. Please think about
participating. Participation is voluntary. Your input will contribute towards cancer
prevention efforts in the region.
If you have any questions or if you’re interested in participating, please contact me at
ariyoo@mail.etsu.edu or 423-439-4877.

Sincerely,
Tosin Ariyo, DrPH(c), MPH
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Appendix B
Focus Group Recruitment Letter
Hello,
My name is Tosin Ariyo. I am a doctoral student in Community and Behavioral Health at
East Tennessee State University (ETSU). I am conducting a study that involves
exploring factors that influence decisions to accept the Human Papilloma Virus (HPV)
vaccine for adolescent girls in Northeast Tennessee.
I am looking for mothers who have daughters between the ages of 11 and 26 years old
to enroll in this study which involves participating in a focus group and completing a
short survey. The focus group will last about 75 minutes and will take place on the
ETSU campus. Please think about participating. Participation is voluntary. Lunch will be
provided.
If you have any questions or if you’re interested in participating, please contact me at
ariyoo@mail.etsu.edu or 423-439-4877.
If you want to learn more about this study or are ready to enroll please follow this link:
Moms_HPVTalk

Sincerely,
Tosin Ariyo, DrPH(c), MPH
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Appendix C
Mother Eligibility Screener
1. Are you a mom or female caregiver?
o Yes
o No
2. Do you have a daughter between the ages of 11 to 26 years old?
o Yes
o No
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Appendix D
INFORMED CONSENT (Interviews)
This Informed Consent will explain about being a participant in a research study. It is important that you
read this material carefully and then decide if you wish to voluntarily participate.
A. Purpose: The purpose of this research study is to learn about factors that influence the decisions
about the Human Papilloma Virus (HPV) vaccine for adolescent girls in the Northeast Tennessee
region.
B. Duration: This one-time session (including interview and short survey) will last 30 minutes
C. Procedures: The procedures, which as a participant in this research will involve you participating
in an interview and completing a short survey. The session will be conducted in a private office in
your practice and will be audio-recorded.
D. Alternative Procedures/Treatments. There are no other options except not to participate.
E. Possible Risks/Discomforts: The possible risks and/or discomforts from your participation in this
research study include: You may feel minor discomfort answering questions about yourself or your
practice. Also, because the session will be audio recorded, there is a potential risk for loss of
confidentiality. You have the right to choose not to answer any questions that make you feel
uncomfortable and to withdraw from the study at any time.
F. Possible Benefits: The possible benefits of your participation in this research study are: as a
result of the discussion topics, you may have a better understanding of HPV and communicating
with patients about health topics. You will also be directly contributing to future health promotion
programs for young women in this region.
G. Compensation in the Form of Payments to Participant: There is no compensation in the form of
payments for participating in this study.
H. Voluntary Participation: Your participation in this research experiment is voluntary. You may
choose not to participate. If you decide to participate in this research study, you can change
your mind and quit at any time. If you choose not to participate, or change your mind and quit, the
benefits or treatment to which you are otherwise entitled will not be affected. You may quit by
calling Tosin Ariyo at 423-439-4877. You will be told immediately if any of the results of the study
should reasonably be expected to make you change your mind about continuing to participate.
I.

Contact for Questions: If you have any questions, problems, or research-related medical
problems at any time, you may call Tosin Ariyo at 423-439-4877, or Dr. Katie Baker at 423-4396720. You may also call the Chairperson of the ETSU Institutional Review Board at 423.439.6054
for any questions you may have about your rights as a research participant. If you have any
questions or concerns about the research and want to talk to someone independent of the
108

research team or you can’t reach the study staff, you may call an IRB Coordinator at 423.439.6055
or 423.439.6002.
J. Confidentiality: Every attempt will be made to see that your study results are kept confidential. A
copy of the records from this study will be stored in Lamb Hall Room 310 on ETSU’s campus for at
least 6 years after the end of this research. The results of this study may be published and/or
presented at meetings without naming you as a participant. Although your rights and privacy will
be maintained, the ETSU IRB, and Tosin Ariyo and her research team have access to the study
records. Your records will be kept completely confidential according to current legal requirements.
They will not be revealed unless required by law, or as described in this form.
You will be given a copy of this consent document for your records.

By signing below, I confirm that I have read and understand this Informed Consent Document and that I
had the opportunity to have them explained to me verbally. You will be given a signed copy of this
informed consent document. I confirm that I have had the opportunity to ask questions and that all my
questions have been answered. By signing below, I confirm that I freely and voluntarily choose to take part
in this research study.

_______________________________________

_________________

Signature of Participant

Date
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INFORMED CONSENT (Focus-Group)
This Informed Consent will explain about being a participant in a research study. It is important that you
read this material carefully and then decide if you wish to voluntarily participate.
A. Purpose: The purpose of this research study are to:
i.
Learn about factors that influence the decisions to accept the Human Papilloma Virus
(HPV) vaccine for adolescent girls in the Northeast Tennessee region
ii.
Gain insight on mother-daughter health communication and relationships
B. Duration: This one-time session (including focus group and survey) will last 75 minutes
C. Procedures: The procedures, which as a participant in this research will involve you participating
in a focus group and completing a short survey. The session will take place in a location on ETSU
campus and will be audio-recorded.
D. Alternative Procedures/Treatments: There are no other options except not to participate.
E. Possible Risks/Discomforts: The possible risks and/or discomforts from your participation in this
research study include: You may feel discomfort answering questions about yourself and/or your
daughter, or talking in a group. Also, because the session will be audio recorded, there is a
potential risk for loss of confidentiality. You have the right to choose not to answer any questions
that make you feel uncomfortable and to withdraw from the study at any time.
F. Possible Benefits: The possible benefits of your participation in this research study are: as a
result of the discussion topics, you may have a better understanding of HPV, mother-daughter
relationships and communicating with your daughter about health topics. You will also be directly
contributing to future health promotion programs for mothers and daughters in this region.
K. Compensation in the Form of Payments to Participant: There is no compensation in the form of
payments for participating in this study.
L. Voluntary Participation: Your participation in this research experiment is voluntary. You may
choose not to participate. If you decide to participate in this research study, you can change
your mind and quit at any time. If you choose not to participate, or change your mind and quit, the
benefits or treatment to which you are otherwise entitled will not be affected. You may quit by
calling Tosin Ariyo at 423-439-4877. You will be told immediately if any of the results of the study
should reasonably be expected to make you change your mind about continuing to participate.
M. Contact for Questions: If you have any questions, problems, or research-related medical
problems at any time, you may call Tosin Ariyo at 423-439-4877, or Dr. Katie Baker at 423-4396720. You may also call the Chairperson of the ETSU Institutional Review Board at 423.439.6054
for any questions you may have about your rights as a research participant. If you have any
questions or concerns about the research and want to talk to someone independent of the
research team or you can’t reach the study staff, you may call an IRB Coordinator at 423.439.6055
or 423.439.6002.
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N. Confidentiality: Every attempt will be made to see that your study results are kept confidential. A
copy of the records from this study will be stored in Lamb Hall Room 310 on ETSU’s campus for at
least 6 years after the end of this research. The results of this study may be published and/or
presented at meetings without naming you as a participant. Although your rights and privacy will
be maintained, the ETSU IRB, and Tosin Ariyo and her research team have access to the study
records. Your records will be kept completely confidential according to current legal requirements.
They will not be revealed unless required by law, or as described in this form.
You will be given a copy of this consent document for your records.

By signing below, I confirm that I have read and understand this Informed Consent Document and that I
had the opportunity to have them explained to me verbally. You will be given a signed copy of this
informed consent document. I confirm that I have had the opportunity to ask questions and that all my
questions have been answered. By signing below, I confirm that I freely and voluntarily choose to take part
in this research study.

_______________________________________

_________________

Signature of Participant

Date
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Informed Consent (Survey)
Dear Participant:
My name is Tosin Ariyo and I am a doctoral student at East Tennessee State University. I am working on my DrPH in
Community and Behavioral Health. As part of my dissertation, I am completing a study on women’s health. The name
of my research study is ‘Women’s Sexual Health and Communication.’
The purpose of this study is to assess young women’s perceptions of their sexual and reproductive health, gender
roles and their primary mode of sexual health communication. I would like to give a brief online survey to ETSU
female college students using Survey Monkey. It should only take about 30 minutes to complete. Since the survey is
administered through Survey Monkey, your SONA ID will be required in order to be awarded participation credit. You
will be asked questions about your demographic information, prior sexual behaviors, knowledge, attitudes, and
beliefs regarding sexual behaviors, perceived health risks, and gender norms. Since this project deals with personal
behavior and feelings, it might cause some minor stress. However, you may also feel better after you have had the
opportunity to express yourselves about your opinions and experiences. This study does not provide any direct
benefit.
Your confidentiality will be maintained to the degree permitted by the technology used. Specifically, no guarantees
can be made regarding the interception of data sent via the Internet by any third parties, as is the case with emails. In
other words, we will make every effort to ensure that your name is not connected with your responses. Specifically,
Survey monkey has security features that will be enabled: IP addresses will not be collected and SSL encryption
software will be utilized. Although your rights and privacy will be maintained, the ETSU IRB (for non-medical
research) and personnel particular to this research, in the Community and behavioral health department, have
access to the study records.
If you do not want to fill out the survey, it will not affect you in any way. You may skip any questions you do not wish
to answer or simply exit the online survey form if you wish to remove yourself entirely.
Participation in this study is voluntary. You may refuse to participate. You can quit at any time. If you quit or refuse
to participate, the benefits or treatment to which you are otherwise entitled will not be affected.
If you have any research-related questions or problems, you may contact me, Tosin Ariyo at (423) 439-4877. I am
working on this project together under the supervision of Dr. Katie Baker. You may reach her at (423) 439 6720. Also,
the chairperson of the Institutional Review Board at East Tennessee State University is available at (423) 439-6054 if
you have questions about your rights as a research subject. If you have any questions or concerns about the
research and want to talk to someone independent of the research team or you can’t reach the study staff, you may
call an IRB Coordinator at 423/439-6055 or 423/439/6002.
Sincerely,
Tosin Ariyo, DrPH(c), MPH
Clicking the AGREE button below indicates:




☐
☐

You have read the above information
You voluntarily agree to participate
You are at least 18 years of age or older
I AGREE
I DO NOT AGREE
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Appendix E
Provider Demographic Survey
1. What is your gender
o Female
o Male
2. What is your clinical degree?
o LPN
o RN
o BSN
o MSN
o DNP
o MD
o DO
3. Please select your area of practice?
o Family medicine
o Internal medicine
o Pediatrics
o Ob-Gyn
4. How many years have you been in practice?
o Less than 5
o 5-10
o 10-15
o 15-20
o 20 or more
5. How would you describe your practice setting?
o Academic
o Clinic
o Hospital
o Other_______________
6. What county is your practice located?
______________________
7. Do you identify as Appalachian?
o Yes
o No
8. Do you often recommend the HPV vaccine to your patients (or their parents)?
o Yes
o No
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Appendix F
Semi-Structured Interview Guide
Date: ____________________
Time Started: _____________
Thank you for agreeing to speak with me today. To get started…
1. Could you tell me about your practice, such as the kinds of patients you see? Demographics?
Age-ranges?
2. Are vaccinations part of your routine care for patients?
3. Could you describe how the vaccination process works in your practice?
Probes:
a. Are there certain mechanisms within your practice that prompt the staff to suggest
vaccines to patients? (Recall/reminder prompts?)
b. Who in the practice usually does the vaccinating (nurses? Medical assistants?)
c. How does vaccination get introduced to parents/patients?
d. Do you feel that there are differences in vaccinating older kids versus the early
childhood patients?
4. Who decides what vaccinations your patients receive?
5. Are there any barriers for the clinic to providing vaccines?
Probes:
a. Cost?
b. Availability?
c. Could you expand on these limitations?
6. What kinds of discussions do you have with parents/patients about newer vaccines, if any?
7. Do you actively recommend specific vaccines? If so, what guides your vaccine
recommendations?
8. What do you think about these vaccines are important or useful for your patient population?
Probes:
a. Does this population have specific health needs or concerns?
b. How do you assess this?
9. How do you convey to parents the importance of these vaccines?
10. Do you ever have adolescents, themselves, ask for specific vaccines?
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HPV specific
11. Could you tell me a little about your experience with the HPV vaccine?
12. What do you think about the vaccine?
13. What concerns do you have, as a practitioner, or personally, about the HPV vaccine?
14. Do you usually recommend the vaccine to parents or their daughters?
a. Could you tell me about how you introduce the vaccine to them?
15. Do you encounter any concerns from parents or teenagers about the HPV vaccine?
16. What is the main reason parents in your practice don’t get the HPV vaccine for their daughters?
17. Is HPV-related disease something you see in your patient population?
18. Do you talk to parents or patients about STIs more generally? Is that a discussion you have when
talking about the HPV vaccine?
19. What do you tell your patients or parents about HPV? Do you discuss HPV independently of
discussing the vaccine? Why or why not?
Probe:
a. Mention of cervical cancer? Genital warts?
20. Do you give the HPV vaccine to your patients? How often?
Probe:
a. Do patients ask for the vaccine?
b. Do parents ask for the vaccine?
c. Are parents or boys/girls more likely to ask for the vaccine?
d. Do you get adolescents coming in requesting the vaccine on their own?
21. Could you describe for me the way in which you introduce the HPV vaccine to your patients or
their parents?
22. Are you aware that there are currently three HPV vaccines?
23. How do you decide which vaccine to provide your patients?
24. Once you have given the first HPV shot, how do you get patients to return for boosters? What
sorts of techniques have you found useful?
25. What are some of the prompts, in your opinion, that might lead to parents asking for the
vaccine?
26. Are there specific groups of patients that you would say are less receptive to the HPV vaccine?
27. What are some of the reasons your patients don’t accept the vaccine?
28. How do you address these reasons?
29. Can you recommend another staff person here to interview?
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Appendix G
Mother Demographic Survey
1. What is your county of primary residence?
______________________
2. Do you identify as Appalachian?
o Yes
o No
3. What is your age? (Please enter number in years)
__________________
4. What is your marital status?
o Married
o Divorced
o Widowed
o Separated
o Never married
5. What is your highest education level?
o Less than high school
o High school diploma/GED
o Associate degree
o Some College
o College degree
o Graduate degree
o Professional degree
6. Are you currently?
o Employed Full-time
o Employed part-time
o Student
o Homemaker
o Student
o Unemployed
o Retired
7. What is your estimated household income?
o Less than $20,000
o $20,000-$34,999
o $35,000-$50,000
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o $50,000-$75,000
o $75,000 or more
8. Is your family covered by any kind of health insurance or some other kind of health care
plan?
o Yes
o No
9. If yes, what kind of health coverage do you have?
o Private health insurance
o Employee health insurance
o Medicaid
o SCHIP (CHIP/Children's Health Insurance Program)
o Military health care (TRICARE/VA/CHAMP-VA)
o Indian Health Service
o State-sponsored health plan
o Other government program
o Single service plan (e.g., dental, vision, prescriptions)
o Employee health insurance
10. My healthcare provider recommended the HPV vaccine for my…
o Daughter
o Son
o Both
o The vaccine has not been recommended
11. Has your daughter received the HPV vaccine?
o Yes
o No
12. Have you or anyone in your family ever being diagnosed with cervical cancer?
o Yes
o No
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Appendix H
Focus Group Guide
Cervical cancer awareness and knowledge
o What do you know about cervical cancer?
o What do you think when you hear cervical cancer?
o Do you worry about cervical cancer for yourself? Your daughter?
 Why? Why not?
HPV Awareness and knowledge
o
o
o
o
o

Before today had you heard about HPV?
What did you hear about it?
Do you worry about your children getting HPV?
Have you heard about the vaccine?
What do you know about the vaccine?

Attitudes towards HPV vaccine
o
o
o
o

What are your thoughts about the vaccine?
Why would you (would you not) choose to vaccinate your daughter?
What concerns would you have about vaccinating your daughter?
What is the main reason you (will) choose to get the HPV vaccine for you
daughter(s)?
o Would you say vaccinating your daughter is beyond your control?
Sources of information
o Where do you get health information?
o Do you talk to your daughter about her health?
 What do you talk about
o Have you talked to your healthcare provider about the HPV vaccine?
 How was the conversation?
o Do you talk about the HPV vaccine or cervical cancer within your social circles
(friends, family etc.)?
Healthcare access
o Who is responsible for healthcare decisions in your household?
o If you wanted to vaccinate your daughter, what obstacles do you think you would
encounter? / When you vaccinated you daughter did you encounter any obstacles?
What were there?
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Perceived Norms
o How do you think people within your social circles would feel about you
vaccinating (or not vaccinating) your daughter?
o In thinking about your communities, what do you think is the general attitude
towards the HPV vaccine
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Appendix I
Women’s Sexual Health and Communication Survey: SONA Survey
Screener
1. Gender at birth?
o Male
o Female
Demographics
2. Enter your SONA ID? _________
3. How old are you? (Years)
o 18-22
o 23-26
o 27-30
o 30+
4. Are you Hispanic or Latino?
o Yes
o No
5. What is your race? (Select one or more responses):
o African-American/Black
o American-Indian/Alaska Native
o Asian
o Caucasian; Non-Hispanic White
o Native Hawaiian/Pacific Islander
6. In what type of environment have you spent most of your life?
o Rural
o Urban

o Suburban
7. In what county did you reside for the majority of your childhood?
_____________
8. Do you identify as Appalachian?
o Yes
o No
Health Education
Sexual and reproductive health involves all matters relating to the reproductive system. It implies the ability to have a satisfying and
safe sex life, the capability to reproduce, and the freedom to decide if, when, and how often to do so.
9. Have you ever received any formal instruction at school, church, a community center or some other place about sexual
abstinence?
o Yes
o No
10. Have you ever received any formal instruction at school, church, a community center or some other place about methods of
birth control?
o Yes
o No
Sexual Health
11. How old were you when you had your first menstrual period? (Years)
_________________
12. Have you ever had sexual intercourse? (This could be either anal, oral or vaginal)
o Yes
o No [skip to #23]
13. At what age did you have your first sexual intercourse? (This could be either anal, oral or vaginal)Years
________________________
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14. Which came first, your first sexual intercourse or your first menstrual period?
o Sexual intercourse
o Menstrual period
15. Have you ever been told by a doctor or nurse that you had a sexually transmitted disease such as genital herpes, genital warts,
chlamydia, syphilis, gonorrhea, AIDS, or HIV infection?
o Yes
o No
16. Since your first menstrual period have you ever visited a clinic for (and received) any kind or reproductive health or birth
control service?
o Yes
o No [Skip to #23]
17. Did you receive formal education at school, church, a community center or some other place about sexual abstinence before or
after your first sexual intercourse?
o Before
o After
18. Did you receive formal education at school, church, a community center or some other place about methods of birth control
before or after your first sexual intercourse?
o Before
o After
19. Have you ever had a Pap smear or Pap test?
o Yes
o No [skip to #34]
20. What was the main reason you had this Pap test?
o Routine Pap test
o Routine physical
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o Last pap test was not normal
o A specific problem
o Never had one and thought you should
o Pre/Post-natal visit
o Other_____________
21. Was this before or after your first sexual intercourse?
o Before
o After
o Not Applicable
22. Have you ever been pregnant?
o Yes
o No
Perception of gender roles
Please tell us how strongly you agree with the following statements
Strongly
Disagree

Moderately
Disagree

23. Women who carry condoms are easy.
24. Men should decide what type of sex to
have.
25. It is a woman’s responsibility to avoid
getting pregnant.
26. Swearing and obscenities are more
repulsive when stated by women
compared to men.
27. The intellectual leadership of a
community should be largely in the hands
of men.
28. The father should have greater authority
than the mother when raising children.
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Neither agree Moderately
nor disagree Agree

Strongly
Agree

29. There are many jobs in which men should
be given preference over women in being
hired or promoted.
30. In my opinion, a woman can suggest
using condoms just like a man can.
31. A man and a woman should decide
together what type of contraception to
use.

Cervical Cancer knowledge
32. What have you heard are the causes of cervical cancer?
o Smoking
o Virus
o STI/STD
o Other_______________
33. Is cervical cancer preventable?
o Yes
o No
34. How can you prevent cervical cancer? [Select all that apply]
o Safe sex
o Vaccine
o Pap Smear
Cervical Cancer attitudes
Strongly
Disagree

Moderately
Disagree

35. Cancer of the cervix is most times
fatal.
36. Cancer of any kind is a death
sentence.
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Neither agree Moderately
nor disagree Agree

Strongly
Agree

37. Cancer of the cervix is beyond my
control.
38. Cancer is a disease that cannot be
avoided.
39. Faith will help me prevent disease
and death.
HPV Knowledge and Perceptions
40. Have you heard about the Human Papilloma virus (HPV)? It is not HIV, HSV, or herpes.
o Yes
o No
41. Where did you get the information?
o Healthcare provider
o Maternal figure
o Other family member
o Friends
o Media (TV, Flyers, Ads)
o School
42. Have you ever been told by a healthcare provider that you had an HPV infection?
o Yes
o No
43. Who can get HPV?
o Males
o Females
44. HPV is transmitted skin-to-skin.
o True
o False
45. HPV is sexually transmitted.
o True
o False
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46. HPV can be transmitted even without exhibited signs or symptoms.
o True
o False
47. Most people with HPV have no symptoms.
o True
o False
48. HPV can be prevented.
o True
o False
49. Condoms can prevent HPV.
o True
o False
50. There is a vaccine to prevent HPV.
o True
o False
51. HPV can cause_____ (Select all that apply)
o Cervical cancer
o Genital warts
o Penile cancer
o Oral Cancer
o Other?
52. HPV can go away without any treatment.
o True
o False
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HPV Attitudes
Strongly
Agree

Moderately
Disagree

Neither
agree nor
disagree

Moderately
Agree

53. I can get HPV
54. The vaccine cannot really prevent
HPV.
55. I am worried about side effects
from the vaccine.

HPV Vaccination
56. Have you received the cervical cancer vaccine, also known as the HPV shot, Cervarix, or Gardasil?
o Yes
o No {Skip to #63}
57. How many doses have you received?
o 1
o 2
o 3
58. How old were you when you received your first HPV vaccine shot? (Years)
_________________
59. Which occurred first-your first sexual intercourse or your first HPV vaccine shot?
o Yes
o No
o Not Applicable
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Strongly
Agree

60. Perceived Control
Strongly
Disagree

Moderately
Disagree

Neither agree
nor disagree

Moderately
Agree

Strongly
Agree

1. For me to receive the HPV
vaccine is easy
2. The decision to receive the
vaccine is beyond my control
3. Whether I get vaccinated or not is
not entirely up to me
61. Perceived Norm
Strongly
Disagree

Moderately
Disagree

1. Most people who are important to
me think I should receive the HPV
vaccine
2. Most people who are important to
me think it would be a good idea to
receive the HPV vaccine
3. Most people who are important to
me want me to get the HPV vaccine
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Neither
agree nor
disagree

Moderately
Agree

Strongly
Agree

62. Vaccine intention
Strongly
Disagree

Moderately
Disagree

Neither
agree nor
disagree

1. I expect to receive the HPV
vaccine
2. I want to receive the HPV
vaccine
3. I intend to be vaccinated
against HPV
Maternal Communication
63. What is your relationship to the person in your life that has been most like a mother to you?
o Biological Mother
o Stepmother
o Adoptive Mother
o Other female mother figure or guardian
64. Have you and your ‘mother’ talked about [check all that apply]
o Cervical Cancer
o HPV
o HPV Vaccine
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Moderately
Agree

Strongly
Agree

65. Maternal Endorsement
Strongly
Disagree

Moderately
Disagree

Neither
agree nor
disagree

Moderately
Agree

Strongly
Agree

1. My mother thinks I should receive
the HPV vaccine
2. My mother thinks it would be a
good idea to receive the HPV
vaccine
3. My mother wants me to get the
HPV vaccine
We are interested in how you communicate with your mother. Please indicate whether you have discussed the following topics with
your mother.

As a teenager, my mother talked with me about…
Yes No
4. The importance of not being pressured to engage in sexual activity
5. Sexual health in general
(Including but not limited to sexual behavior, safe sex practices etc.)
6. Birth control
7. Sexually transmitted diseases
8. Safe sex practices
9. Sexual intercourse
10. Abstinence
11. The warning signs for cervical cancers
12. HPV Vaccination
13. Cervical cancer screening (Pap smears, HPV tests)
14. Violence against women
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Please indicate your perception of how receptive you were to your communication about each topic using the scale shown below,
indicating whether you disagree or agree. If you have not talked with your mother about a topic, please choose "we have not talked
about it."

I was receptive when my mother and I talked about…
Strongly
Disagree

Moderately
Disagree

15. The importance of not being
pressured to engage in sexual
activity
16. Sexual health in general
(Including but not limited to
sexual behavior, safe sex
practices etc.)
17. Birth control
18. Sexually transmitted diseases
19. Safe sex practices
20. Sexual intercourse
21. Abstinence
22. The warning signs for cervical
cancers
23. HPV Vaccination
24. Cervical cancer screening (Pap
smears, HPV tests)
25. Violence against women
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Neither agree
nor disagree

Moderately
Agree

Strongly
Agree

We have
not
talked
about it

Please answer these questions with respect to your relationship with your mother figure you indicated earlier.
We are interested in the characteristics of your relationship with your mother. Please indicate how much you agree or
disagree with the following statements by checking one box in each row.

Mother-Daughter Relationship
Strongly
Disagree

26. When we talk about important topics, my mother has
something useful to say.
27. My mother gives me good advice.
28. The advice my mother gives me is helpful when we talk
about important topics.
29. I go to my mother for help when I need advice about
something important.
30. My mother knows a lot about things that are important to
me.
31. I know that my mother wants what is best for me.
32. My mother keeps her promises to me.
33. I can trust my mother when we talk.
34. My mother is honest with me.
35. My mother is there for me when I want to talk to her.
36. My mother understands my problems and worries.
37. My mother lets me make my own decisions.
38. Overall, I am satisfied with the way my mother and I
communicate.
39. When we talk about important topics, my mother wants to
hear what I have to say and think.
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Disagree

Neither
agree nor
disagree

Agree

Strongly
Agree

40. When I talk about important things with my mother, she
tells me about her past experiences.
41. When I talk about important things with my mother, she
tells me things about her life, even if they are embarrassing.
42. When I talk about important things with my mother, she
tells me what things were like for her when she was my
age.
43. My mother is good about not “lecturing” me too much.
44. It is difficult for my mother and me to find time to talk.
45. My mother is too busy when I want to talk.
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